UCLA UCLA Previously Published Works

Title

Whole genome sequence association analysis of fasting glucose and fasting insulin levels in diverse cohorts from the NHLBI TOPMed program

Permalink

https://escholarship.org/uc/item/4rg100w1

Journal Communications Biology, 5(1)

ISSN

2399-3642

Authors

DiCorpo, Daniel Gaynor, Sheila M Russell, Emily M <u>et al.</u>

Publication Date

2022

DOI

10.1038/s42003-022-03702-4

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <u>https://creativecommons.org/licenses/by/4.0/</u>

Peer reviewed

communications biology

ARTICLE

https://doi.org/10.1038/s42003-022-03702-4

OPEN

Whole genome sequence association analysis of fasting glucose and fasting insulin levels in diverse cohorts from the NHLBI TOPMed program

The genetic determinants of fasting glucose (FG) and fasting insulin (FI) have been studied mostly through genome arrays, resulting in over 100 associated variants. We extended this work with high-coverage whole genome sequencing analyses from fifteen cohorts in NHLBI's Trans-Omics for Precision Medicine (TOPMed) program. Over 23,000 non-diabetic individuals from five race-ethnicities/populations (African, Asian, European, Hispanic and Samoan) were included. Eight variants were significantly associated with FG or FI across previously identified regions *MTNR1B, G6PC2, GCK, GCKR* and *FOXA2*. We additionally characterize suggestive associations with FG or FI near previously identified *SLC30A8, TCF7L2,* and *ADCY5* regions as well as *APOB, PTPRT,* and *ROBO1*. Functional annotation resources including the Diabetes Epigenome Atlas were compiled for each signal (chromatin states, annotation principal components, and others) to elucidate variant-to-function hypotheses. We provide a catalog of nucleotide-resolution genomic variation spanning intergenic and intronic regions creating a foundation for future sequencing-based investigations of glycemic traits.

A full list of authors and their affiliations appears at the end of the paper.



ype 2 diabetes (T2D) and insulin resistance are complex genetic conditions often characterized by disruptions of normal levels of fasting glucose (FG) and fasting insulin (FI)¹. These traits are influenced by a spectrum of common to rare genetic variation $^{2-7}$ with most evidence coming from genome-wide association studies (GWAS)^{8,9}, exome arrays^{2,3,6}, whole-exome sequencing², and small samples of low-pass wholegenome sequencing (WGS)^{4,10}. These efforts have found over 100, mostly common (minor allele frequency (MAF) > 0.05), variants associated with FG or FI, including those in non-coding and intergenic spaces^{2-4,6,8,9}. We expand on these previous studies by assessing common, low frequency (MAF < 0.05), and rare (MAF < 0.01) variants through comprehensive WGS association analysis in diverse population cohorts in NHLBI's Trans-Omics for Precision Medicine (TOPMed) program. The current study aims to better understand the variants at GWAS loci through multiple approaches including discovery and fine-mapping in both coding and non-coding regions as well as aggregate rare variant testing using both protein-coding variants and intergenic variants. In addition, we explore ancestry-specific results through our four included race/ethnicities and one population group: African, Asian, European, Hispanic, and Samoan, respectively. Finally, we characterize all reported regions with annotations including chromatin states, annotation principal components (PCs), expression quantitative trait loci (eQTL), and others from recent annotation accumulation efforts including the Diabetes Genome Atlas (DGA).

Results

Phenotypes and genotypes in the NHLBI TOPMed program. We identified and characterized common and rare variants associated with FG and (natural log-transformed) FI through association tests using WGS data from fifteen cohorts in TOPMed (Supplementary Table 1). As in prior quantitative trait analyses, we excluded individuals with diabetes (by glycemia or medication), resulting in a total sample size of 26,807 individuals with FG and 23,211 individuals with FI. This represents a diverse sample of four self-reported race/ethnicities and one population group including African, Asian, European, Hispanic, and Samoan, respectively, and our total sample was >40% non-European (Supplementary Tables 2-3). In addition to use of genetic ancestry adjustments in our models (see the "Methods" section), we used participant's selfreported race/ethnicity to assign individuals to one of five groups for stratified analyses or inclusion as a covariate. Individuals were given a single label to infer their ancestry, but each group represents a diverse cross-section of race, culture, or admixture. Trait measures were harmonized across cohorts and assays and adjusted for self-reported race/ethnicity, study age, sex, and body mass index (BMI; Supplementary Tables 2-3, "Methods"). We assessed 60 M variants from the TOPMed Freeze 5b WGS data freeze for each trait using single-variant testing (minor allele count, MAC > 20) in pooled and race/ethnicity-specific approaches. We used a significance threshold of $P < 1.0 \times 10^{-9}$ as has been established for WGS studies including African ancestry¹¹. We also separately report signals identified with $P < 5.0 \times 10^{-8}$ as suggestively associated with either trait. These suggestively associated signals are reported to characterize potential regions of interest with our available annotations for use in future higher-powered studies. We further performed rare variant testing (MAF < 0.01) using aggregate burden and SKAT tests in both gene centric and genetic region approaches. We computed 95% credible sets for each distinct common variant signal conditioned on any other identified signal at the locus ("Methods", Supplementary Data 1). 99% credible sets are also reported for signals identified through the pooled analysis (Supplementary Data 2), with a median size of 12

variants. This is 20% smaller than a recent multi-ethnic GWAS of glycemic traits¹² which reported a median 99% credible set size of 15.

Whole-genome sequence significant associations with fasting glucose and insulin. We identified eight distinct variants significantly associated with FG or FI across five gene regions in the pooled race/ethnicity analysis ($P < 1.0 \times 10^{-9}$, Table 1). These include previously identified *MTNR1B*, *G6PC2*, *GCK*, *GCKR*, and *FOXA2* gene regions (Supplementary Data 3–4). *MTNR1B* had a distinct secondary signal after conditioning on the lead variant. *G6PC2* had three distinct association signals, one of which was rare (MAF < 0.01), as determined by sequential conditional analysis. These distinct secondary and tertiary signals are also reported in Table 1 (locus-wide significance threshold of 1.0×10^{-5} , "Methods") and further described in the following sections. Manhattan and QQ plots for single variant analyses of FG and FI are shown in Supplementary Fig. 1.

Our significantly associated variants replicate previous GWAS findings, which are summarized in Supplementary Data 3–4. We further characterize these variants in the context of sequencing and related available resources as summarized in Fig. 1. We used the Diabetes Epigenome Atlas (DGA) and TOPMed resources to provide functional annotations including chromatin states, annotation principal components (aPCs)¹¹ that each provide a summary of related functional annotations via PCA ("Methods"), and expression quantitative trait loci (eQTL) from adipose, pancreas, liver and skeletal muscle. In addition to variant descriptions in Fig. 1, regional locus plots with tissue-specific annotations of reported loci in Supplementary Fig. 2, and associations of reported loci with related traits in Supplementary Fig. 3 and Supplementary Data 5. Selected regions are further described based on the data below.

MTNR1B intronic variant rs10830963 ($P = 9.1 \times 10^{-46}$) has been characterized as a strong signal for insulin secretion¹³; this variant is in a weak transcription chromatin state in islets, is a metabolite QTL for glucose^{14,15}, and is a pancreatic-islet-specific eQTL associated with the expression of *MTNR1B*¹⁶. Identified after conditioning on the primary variant rs10830963 in the *MTNR1B* region, intronic variant rs73560545 occurs upstream of the primary signal and had a lowering effect on FG, in contrast to the primary signal which had a glucose-raising effect. While this is a well-known region in the context of these traits, this secondary variant at rs73560545 has not been previously identified in the reviewed literature (Supplementary Data 3–4).

The GCKR locus had a significant association with both FG and FI at rs1260326 ($P = 6.1 \times 10^{-21}$, 7.2×10^{-13} , respectively) with functional activity suggested by its relatively high aPC-Epigenetics and aPC-Transcription-Factor values. This variant is also an eQTL and pQTL associated with many genes and proteins, most relevantly with insulin¹⁷. GCKR and rs1260326 have been previously described in previous studies for both traits (Supplementary Data 3–4).

The FOXA2 locus has also been previously found to be associated with glycemic traits, regulating gene expression for glucose sensing in pancreatic beta cells¹⁸. We observe one FGassociated signal at rs3833331 ($P = 5.4 \times 10-10$), a variant moderately linked to previously identified FOXA2 lead variants rs6048205 and rs6048216, and based on conditional analysis is likely the same signal. The variant rs3833331 is in the 3' UTR of the gene and classified as a CAGE promoter, GeneHancer, and SuperEnhancer. It is in an active TSS chromatin state for both pancreas and islets. Our identified variant rs3833331 is frequent in African individuals, while it has relatively low frequency in both European and Hispanic race/ethnicities.

Table 1 Distinct	signals at loci s	Table 1 Distinct signals at loci significantly associated with glyce	liated with glycemic tr	raits FG a	emic traits FG and FI in TOPMed, $P < 1 \times 10^{-9}$.	ed, <i>P</i> < 1 × 10 ⁻⁹ .					
Trait	Population	Nearest gene	MarkerID ^a	EA	rsID	Annotation	EAF	P-value	Beta	SE	Conditioned on
Fasting glucose	Pooled	MTNR1B	11:92975544:C:G	U	rs10830963	Intronic	0.24	9.1×10^{-46}	0.07	0.01	
			11:92884161:G:A ^b	IJ	rs73560545	intronic	0.83	5.7×10^{-6}	0.03	0.01	rs10830963
		G6PC2	2:168906638:T:C	U	rs560887	Intronic	0.82	6.8×10^{-37}	0.07	0.01	
			2:168900420:A:G ^b	A	rs540524	2KB upstream	0.66	9.9×10^{-14}	0.04	0.01	rs560887
			2:168907981:T:C c	⊢	rs2232326	Missense	0.99	5.0×10^{-6}	0.15	0.03	rs560887,
											rs540524
		GCK	7:44189469:C:T	⊢	rs1799884	2KB upstream	0.18	3.9×10^{-28}	0.06	0.01	
		GCKR	2:27508073:T:C	U	rs1260326	Missense	0.65	6.1×10^{-21}	0.04	0.01	
		FOXA2	20:22581688:A:AG	A	rs3833331	3′ UTR	0.85	5.4×10^{-10}	0.04	0.01	
Fasting insulin	Pooled	GCKR	2:27508073:T:C	υ	rs1260326	Missense	0.67	7.2×10^{-13}	0.03	0.01	
EA effect allele, EAF effect a ^a Chromosome, position(Hg ^b Indicates secondary signal ^c Indicates tertiary signal for	t allele frequency, EU Ei 4g38), reference allele, a ial.	EA effect allele, EAF effect allele frequency, EU European, HS/L Hispanic/Latinx. Chromosome, position(Hg38), reference allele, alternative allele of the genetic bindicates secondary signal.	EA effect allele, EAF effect allele frequency, EU European, HS/L Hispanic/Latinx. ^{aC} hromosome, position(Hg38), reference allele, alternative allele of the genetic variant with the lowest P-value and highest posterior probability representing a distinct association at a locus. ^b Indicates secondary signal for association at significance level P <1 ×10 ⁻⁵ and MAC > 20 after conditional analysis.	le and highest sis.	posterior probability rep	resenting a distinct associat	ion at a locus.				

ARTICLE

Rare variant aggregate testing performed using both genecentric and genetic region approaches identified one significantly associated region with FG at the known G6PC2 locus, described in the next section (Supplementary Data 6-7). No rare variant aggregate signals were found to be associated with FI that were not composed mostly of singletons (Supplementary Data 8-9). Manhattan plots for region-based rare variant aggregate analysis in Supplementary Fig. 4.

Refinement of the multi-allelic associations at the known G6PC2 locus. At the known FG and T2D-associated G6PC2 locus^{2,3}, we observed several previously identified variant associations with FG (Fig. 2). In single variant analyses, we identified three distinct association signals, the third of which was a previously identified association after conditioning on two previously reported common GWAS variants, rs560887 (primary signal, $P = 6.8 \times 10^{-37}$) and rs540524 (secondary signal, $P = 9.9 \times 10^{-14}$). The rare missense variant rs2232326 (tertiary signal, $P = 5.0 \times 10^{-6}$) is annotated¹⁹ by the aPCs as disruptive and likely damaging, with a score falling in the top 7% distribution of the aPC representing "protein function" (aPC-Protein Function = 31.5, top 7% genome-wide). In addition, rs2232326 appears to be highly conserved, with a score falling in the top 0.13% of the distribution of an aPC representing "conservation" (aPC-Conservation = 28.8, top 0.13% genome-wide). The genomic region surrounding rs2232326 is annotated to be in a weakly transcribed chromatin state, relative to the genome, in islets and this variant is near the transcription end site (Fig. 2). The frequency of the C allele at rs2232326 was <0.01 in all race/ethnicity groups except for the Asian group where the frequency was 0.03 (gnomAD: East Asian AF = 0.05, Overall AF = 0.01). In aggregate gene-centric testing of all 75 rare missense variants in G6PC2, this previously identified rare (MAF = 0.01) variant rs2232326, along with variant rs2232323 (MAF = 0.01), contributed the most to the significant association test statistic ($P_{\text{Burden},1,1} = 1.4 \times 10^{-10}$, Supplementary Data 6).

Given the multiple distinct signals at G6PC2, we performed a haplotype analysis to evaluate the contribution of rare variants and identify allele-specific effects. We extended the haplotype analysis of Mahajan et al.³ (rs560887, rs138726309, rs2232323, rs492594) to include our secondary (rs540524) and tertiary (rs2232326) signals. Our secondary signal is in moderate linkage $(r^2 = 0.58)$ to the previously haplotyped rs492594 and the effect allele A has a glucose-raising effect in both marginal and conditional analyses (Supplementary Table 4 and Table 1). We observed consistent direction of effects as the previous haplotype analysis, demonstrating the reliability of associations identified in the present TOPMed sample. Both haplotypes containing the C allele of the tertiary signal at rs2232326, the variant with the largest effect size included in the analysis, had glucose-lowering effects. The largest glucose-lowering effects at G6PC2 were observed at the two haplotypes each carrying a rare allele: rs2232326 (rs560887-C, rs138726309-C, rs2232323-A, rs492594-C, rs540524-G, rs2232326-C, Beta = -0.15 + (-0.00002)and rs2232323 (rs560887-T, rs138726309-C, rs2232323-C, rs492594-G, rs540524-A, rs2232326-T, Beta = -0.11 + -0.00008, Supplementary Table 4).

Additional suggestive associations with fasting glucose and insulin. We further report twelve distinct variants suggestively associated with FG or FI across ten gene regions in the pooled race/ethnicity analysis and ancestry-specific analyses $(P < 5.0 \times 10^{-8}; \text{ Table 2})$. These include previously identified SLC30A8, TCF7L2, and ADCY5 gene regions (Supplementary Data 3-4). Other regions not previously identified include APOB, PTPRT, ROBO1 and those described in the ancestry-specific section below. SLC30A8 and PTPRT have distinct secondary signals identified through conditional analysis, which are also




Fig. 1 Characterization of significant and suggestive single-variant signals associated with fasting glucose and fasting insulin in TOPMed. TOPMed features of distinct, significant and suggestive signals associated with fasting glucose and fasting insulin (log-transformed) in pooled analysis. *P*-values (unconditional –log10-transformed) for glycemic and related traits (HbAa1c and type 2 diabetes) and effect allele frequency (with respect to the pooled analysis effect allele) across race/ethnicities in TOPMed are reported. Chromatin states at relevant tissues were drawn from two sets of experiments from DGA^{46,47}; annotation PCs provide summaries of multi-faceted variant function; variants that are significant eQTLs in relevant tissues are denoted. EAF, effect allele frequency for TOPMed sample; EnhA1, Active Enhancer 1; EnhA2, Active Enhancer 2; Het, Heterochromatin; Quies, Quiescent/Low; ReprPC, Repressed PolyComb; ReprPCWk, Weak Repressed PolyComb; TssA, Active TSS; TssFlnk, Flanking TSS; TxWk, Weak Transcription; ZNF/Rpts, ZNF genes & repeats.

reported in Table 2 (locus-wide significance threshold $P < 1.0 \times 10^{-5}$). We outline these suggestive signals and the corresponding gene regions below to provide annotation and description and to provide context for investigation of these signals in future, larger studies.

In the *ADCY5* region, variant rs72964564 $(P = 2.8 \times 10^{-8})$ showed suggestive association with FG and is highly linked $(r^2 = 0.86$ in the present study sample) with the known FG-associated variant rs11708067. Both *ADCY5* variants are designated GeneHancer and SuperEnhancer variants, and rs72964564 is in an active enhancer state for adipose tissue and is an eQTL associated with ADCY5 expression in pancreatic islets¹⁶. *ADCY5* and rs72964564 have been previously identified in studies of FG (Supplementary Data 3–4).

Near the *APOB* region a suggestively associated variant at rs478588 ($P = 2.9 \times 10^{-9}$) has not previously identified (Supplementary Data 4). Variant rs478588 has robust associations with lipid traits²⁰ and significant parent-of-origin effects on metabolic traits²¹. Lipid traits have been studied for pleiotropy with glycemic traits but have been inconclusive with respect to *APOB*. Replication was attempted in UK-BioBank (UKBB) with consistent direction of effect and P = 0.01, but it should be noted UKBB sample used was not based on WGS data (Supplementary Table 5).

We identified a pair of suggestively FG-associated signals in islet-specific active enhancer regions at the known *SLC30A8* locus. The primary signal is at variant rs35859536 ($P = 1.0 \times 10^{-9}$), which is an intergenic variant 2.5KB downstream of *SLC30A8*. This variant is highly linked ($r^2 > 0.95$) to previously identified lead variants rs11558471 and rs3802177 at *SLC30A8*, both of which are in the 3' UTR. This is a known T2D susceptibility locus and has been identified as associated with triglyceride levels²². Our lead variant is also significantly associated with T2D in TOPMed (Supplementary Data 5)²³. To evaluate potential causal variants ("Methods") we performed credible set analyses and found rs35859536 has a posterior

probability (PP) of 0.48; other variants in the 95% credible set with PP of at least 0.05 were either missense or in the 3' UTR, are highly linked with this lead variant ($r^2 > 0.97$), and were significantly associated with FG in previous studies^{2,8,24}. Our lead variant, along with other previous lead variants, is in an active enhancer 2 region for islets; rs35859536 is also mapped as an accessible chromatin site in islet of Langerhans given inflammatory-inducing cytokine exposure²⁵. Replication of these signals was attempted in the METSIM cohorts, and we observe nominal significance of the primary signal with a consistent direction of effect, while the secondary signal was too low frequency in this cohort to estimate an effect (Supplementary Table 6).

The secondary suggestively FG-associated signal at the *SLC30A8* locus is at variant rs542965166 ($P = 1.9 \times 10^{-6}$). This intergenic variant is only observed in individuals in the Asian population (Asian EAF = 0.007); this race/ethnicity-specificity is replicated in gnomAD²⁶ where the allele is only observed in East Asians at a rare frequency. This secondary, race/ethnicity-specific signal is not highly linked to other variants in the region, which may indicate that this is a distinct, secondary signal and requires further follow-up in an Asian population.

Upstream of the *ROBO1* locus we identified a suggestively novel (to the best of our knowledge) FI-associated rare variant, rs539973028 ($P = 4.7 \times 10^{-8}$). This locus has previously been studied for *SLIT-ROBO* signaling and expression in T2D complication diabetic retinopathy²⁷. *ROBO1* has been associated with the glycemia-related traits of BMI and waist-to-hip ratio^{28–30} and is commonly expressed in muscle and skin³¹. This variant is only observed in the African population of TOPMed and gnomAD²⁶. It is intergenic and in a weakly transcribed region in islets.

We identified a pair of distinct, suggestively novel (to the best of our knowledge) rare variant signals associated with FI near the *PTPRT* gene (Table 2). The primary signal, rs185250851 $(P = 2.1 \times 10^{-8})$, is an intronic variant. It is rare in all tested




Fig. 2 Regional investigation of three conditionally significant signals associated with fasting glucose in the *G6PC2* **locus in TOPMed.** Regional association plot of *-*log10 *P* values by genomic position for sequential conditional single-variant analyses. The linkage disequilibrium (*r*²) between the primary signal (rs560887, 2:168906638:T:C), as defined by the highest posterior probability, and variants in the region for each panel as calculated in TOPMed is indicated in the colors of the points. The chromatin states at four relevant tissues⁴⁷ and annotation PCs are provided across the region. APC1, APC Epigenetics, APC2, APC Conservation, APC3, APC Protein, APC9, APC Distance to TSS/TSE; EnhA1, Active Enhancer 1; EnhA2, Active Enhancer 2; Het, Heterochromatin; Quies, Quiescent/Low; ReprPC, Repressed PolyComb; ReprPCWk, Weak Repressed PolyComb; TssA, Active TSS; TssFlnk, Flanking TSS; TxWk, Weak Transcription; ZNF/Rpts, ZNF genes & repeat. population groups and not observed in Asian individuals, as validated in gnomAD²⁶. The secondary signal at variant rs78618809 ($P = 5.9 \times 10^{-6}$) is in an intergenic region. This variant is within the top 5% of variants with respect to an aPC representing "Distance to TSS/TSE," a composite measure of individual annotations indicating low variant distance to the endpoints of the intergenic region. This variant is rare overall, but observed frequently (EAF = 0.07) in the African ancestry population. This gene has previously been associated with BMI, which has moderate genetic correlation (previously estimated as $\rho_{\rm g} = 0.48$) with FI^{20,21}. The expression of this gene is most commonly associated with variants as eQTLs in pancreas in GTEx³¹. The multi-ethnic TOPMed sample permits the identification of this signal, which requires a sufficiently diverse sample.

Race/ethnicity-specific analyses associated with fasting glucose and insulin. In race/ethnicity-specific analyses, we observed two not previously identified race/ethnicity-specific rare variant suggestive associations with FG in individuals of the Hispanic/Latinx population (Table 2). The first signal, rs1328056 ($P = 3.6 \times 10^{-8}$), is an intronic variant in the *HS6ST2* gene, which has been associated with obesity and impaired glucose metabolism in mouse studies¹³. The second signal is an intergenic variant near the *ATPSCKMT* gene, rs13361160 ($P = 3.1 \times 10^{-8}$) which is associated with eosinophil counts, a measure that has been negatively correlated with FG¹⁴. We would require further data from individuals from the Hispanic/Latinx population in order to replicate these suggestive signals.

We identified two suggestively novel (to the best of our knowledge) race/ethnicity-specific rare alleles associated with FI. In the European population, rs775018107 ($P = 4.5 \times 10^{-8}$) at the *LINC00704/LINC00705* locus was suggestively associated with FI (Table 2). We also identified a suggestive FI association in the Samoan population cohort at rs117592405 ($P = 3.3 \times 10^{-8}$); this intronic variant was not replicated in an independent Samoan cohort using imputed genotypes (N = 1401, Supplementary Table 7).

Enrichment of trait-associated variants in chromatin states. We assessed whether our trait-associated variants were found more often than expected in a particular chromatin state using the tool GREGOR (Genomic Regulatory Elements and Gwas Overlap algorithm)¹⁵ ("Methods"). We observe that fasting glucose-associated variants are found more often in "Active Enhancers", "Weak Transcription", and "Genic Enhancer" chromatin states in Islets (P < 0.05, Supplementary Table 8). This complements findings from Chen et al.¹² showing similar enrichment of glycemic trait-associated signals in islet enhancers.

Discussion

In this paper, we leveraged high-coverage WGS data in large multi-ethnic population-based cohorts to assemble a comprehensive catalog of nucleotide-resolution genomic variation associated with the key diabetes-related quantitative traits FG and FI. Our analysis covered intergenic and intronic regions to a MAC of 20 in single variant analysis and combines base pair variation with tissue-specific epigenomic annotation to illuminate variantto-function hypotheses in diabetes pathobiology.

A strength of the present analysis is the inclusion of individuals from 15 cohorts, comprised of four major race/ethnicity groups and one population group(African, Asian, European, Hispanic/ Latinx, and Samoan, respectively). Some of our reported regions

COMMUNICATIONS BIOLOGY https://doi.org/10.1038/s42003-022-03702-4

were either mostly or exclusively present in a single race/ethnic These include the secondary SLC30A8 variant group. rs542965166 only observed in the Asian group, ROBO1's rs539973028 only present in African group, and others. Previous genetic studies of glycemic traits have included samples primarily from individuals of European ancestry, but increasingly a larger degree of African ancestry. The most recent meta-analysis by the MAGIC consortium included ~30% non-European ancestry individuals, demonstrating that a number of trait-associated loci that would have been undetected in samples exclusively of European ancestry¹⁸. While extending the genetic ancestries studied beyond European populations, the MAGIC results were subject to the limitation of imputation by the 1000 Genomes Project reference panel, so most rare and ancestry-specific variation was still not assessed. In addition, we observe a 20% decrease in average 99% credible set size from the MAGIC results suggesting value of WGS in fine-mapping.

This analysis benefits from the availability of whole-genome sequencing data provided by the TOPMed Program of the NHLBI's Precision Medicine Initiative^{10,32}. Previous studies have been limited by reliance on imputation or minimal sample sizes for data with sequencing paired with glycemic phenotypes. The GoT2D study has performed WGS in a limited sample, contributing to the larger DIAMANTE meta-analysis of summary statistics but relying on imputation for complete genotyping of most samples³³. The UKBB study includes a large set of primarily European individuals with whole-exome sequencing; however, the sample size with measured fasting glycemic traits is limited as described in the validation study. One of the most expansive efforts, a MAGIC collaboration^{8,34}, has performed extensive analyses for glycemic traits, but results rely primary on Exome Chip data and thus have limited coverage of intergenic and intronic regions⁶. Our significant findings replicate previous GWAS findings in terms of gene regions, but we are able to characterize these regions in great detail and report on specific variants which may not previously described in these known regions, such as the secondary MTNR1B-associated variant.

In addition to reporting significant and suggestive associations, we provide detailed characterization of each locus in terms of functional annotations, chromatin states, quantitative trait loci, related trait associations and more. The *G6PC2* in particular was described in terms of allelic effects and provided functional characterization of low-frequency signal, demonstrating the glucose-lowering effects of rare alleles and islet-specificity of this locus's associations. Many of our reported regions lie in enhancer or transcription start site chromatin states, and we particularly see significant enrichment in enhancer states in islets. This agrees with findings of previous GWAS and the expected relevant tissues for glycemic traits. We provide this data and the visualizations for use in future investigation of these loci.

A limitation of this study is our smaller sample size compared to the most recent GWAS. Our significant single variant results are all found near previously identified gene regions. Also, many of our suggestively novel results lack substantiating replication, particularly those which are race/ethnicity specific. We analyzed independent studies with genetic data to investigate associations significant in TOPMed; we were unable to replicate potentially novel signals in these external cohorts. This may be attributable to limitations in the available replication studies' samples with respect to size, race/ethnicity and imputed versus WGS genotypes. To support the understanding of these signals, we consider a set of tissue-specific chromatin states, an effort that would benefit from further tissue-specific characterization across functional measures. This could also help inform the underlying biological mechanisms of glycemic regulation and its role in diabetes.

SLC30A8 B:117179236:C:T C r:s35859536 2.5KB downstream 0.74 1.0 × 10 ⁻⁹ 0.03 0.01 B:117258547:C:Tb T r:s542965166 Intronic 0.001 1.9 × 10 ⁻⁶ 0.50 0.11 1 APOB 2:21074277:A:G A r:s542965166 Intronic 0.001 1.9 × 10 ⁻⁶ 0.50 0.11 1 APOB 2:21074277:A:G A r:s7495858 30KB upstream 0.29 2.9 × 10 ⁻⁹ 0.03 0.01 TCF7L2 10:112998590:C:T T r:s7903146 Intronic 0.29 2.9 × 10 ⁻⁹ 0.03 0.01 ADCY5 3:123335923:A:C A r:s77964564 Intronic 0.25 2.0 × 10 ⁻⁸ 0.03 0.01 H56573 13:96407609:A:G G r:s738056 Intronic 0.26 2.8 × 10 ⁻⁸ 0.03 0.03 0.03 0.01 H56573 13:96407609:A:G r rs7328056 Intronic 0.02 2.8 × 10 ⁻⁸ 0.03 0.05 PTPRT </th <th>$\begin{array}{c ccccccccccccccccccccccccccccccccccc$</th> <th>8:117179236:C:T C rs35859536 2.5KB downstream 0.74 1.0 × 10⁻⁹ 0.03 0.01 8:117258547:C:T^b T rs542965166 Intronic 0.001 19 × 10⁻⁶ 0.50 0.11 r 8:117258547:C:T^b T rs542965166 Intronic 0.001 19 × 10⁻⁶ 0.50 0.11 r 2:21074277:A:G A rs77964566 Intronic 0.29 2.9 × 10⁻⁹ 0.03 0.01 3:12335923:A:C A rs77964566 Intronic 0.28 0.02 2.8 × 10⁻⁸ 0.03 0.01 3:12335923:A:C A rs72964566 Intronic 0.28 0.02 2.8 × 10⁻⁸ 0.03 0.01 3:1069711:T:C C rs1328056 Intronic 0.02 2.8 × 10⁻⁸ 0.30 0.05 5:10169711:T:C C rs1335160 Intronic 0.02 2.8 × 10⁻⁸ 0.30 0.05 2:0:4105911:T:C C rs135250851 Intronic 0.02 2.1 × 10⁻⁸ 0.31<!--</th--><th>Trait</th><th>Population</th><th>Nearest gene</th><th>MarkerID^a</th><th>EA</th><th>rsID</th><th>Annotation</th><th>EAF</th><th>P-value</th><th>Beta</th><th>SE</th><th>Conditioned on</th></th>	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	8:117179236:C:T C rs35859536 2.5KB downstream 0.74 1.0 × 10 ⁻⁹ 0.03 0.01 8:117258547:C:T ^b T rs542965166 Intronic 0.001 19 × 10 ⁻⁶ 0.50 0.11 r 8:117258547:C:T ^b T rs542965166 Intronic 0.001 19 × 10 ⁻⁶ 0.50 0.11 r 2:21074277:A:G A rs77964566 Intronic 0.29 2.9 × 10 ⁻⁹ 0.03 0.01 3:12335923:A:C A rs77964566 Intronic 0.28 0.02 2.8 × 10 ⁻⁸ 0.03 0.01 3:12335923:A:C A rs72964566 Intronic 0.28 0.02 2.8 × 10 ⁻⁸ 0.03 0.01 3:1069711:T:C C rs1328056 Intronic 0.02 2.8 × 10 ⁻⁸ 0.30 0.05 5:10169711:T:C C rs1335160 Intronic 0.02 2.8 × 10 ⁻⁸ 0.30 0.05 2:0:4105911:T:C C rs135250851 Intronic 0.02 2.1 × 10 ⁻⁸ 0.31 </th <th>Trait</th> <th>Population</th> <th>Nearest gene</th> <th>MarkerID^a</th> <th>EA</th> <th>rsID</th> <th>Annotation</th> <th>EAF</th> <th>P-value</th> <th>Beta</th> <th>SE</th> <th>Conditioned on</th>	Trait	Population	Nearest gene	MarkerID ^a	EA	rsID	Annotation	EAF	P-value	Beta	SE	Conditioned on
8:117258547.C:Tb T rs542965166 Intronic 0.001 19×10 ⁻⁶ 0.50 0.11 1 APOB 2:21074277:A:G A rs732965166 Intronic 0.29 29×10 ⁻⁹ 0.03 0.01 TCF7L2 10:112998590:C:T T rs77903146 Intronic 0.25 2.0×10 ⁻⁸ 0.03 0.01 ADCY5 3:123335923:A:C A rs77964564 Intronic 0.25 2.0×10 ⁻⁸ 0.03 0.01 HS/L H5/L H56573 3:123335923:A:C A rs72964564 Intronic 0.25 2.0×10 ⁻⁸ 0.03 0.01 Poled PTRT 3:13:96407609:A:G G rs72964564 Intronic 0.02 3.6×10 ⁻⁸ 0.03 0.01 Poled PTRT 2:10169711:F:C C rs13361160 Internic 0.02 2.1×10 ⁻⁸ 0.30 0.05 Pooled PTRT 20:42752773:G:A A rs185550851 Intronic 0.02 2.1×10 ⁻⁸ 0.30 0.05 ROBOI 3:798123477:C:7b T rs78618809 Intergenic <td< td=""><td>8:117258547:C:T^b T rs542965166 Intronic 0.001 19×10⁻⁶ 0.50 0.11 1 2:21074277:A:G A rs478588 30KB upstream 0.29 2.9×10⁻⁹ 0.03 0.01 2:21074277:A:G A rs478588 30KB upstream 0.29 2.9×10⁻⁹ 0.03 0.01 3:123335923:A:C A rs77903146 Intronic 0.25 2.0×10⁻⁸ 0.03 0.01 3:123355923:A:C A rs72964564 Intronic 0.25 2.0×10⁻⁸ 0.03 0.01 3:129503:A:C A rs72964564 Intronic 0.20 2.8×10⁻⁸ 0.03 0.01 13:96407609:A:G G rs1328056 Intronic 0.02 3.6×10⁻⁸ 0.03 0.01 5:0169711:F:C C rs1335160 Intergenic 0.02 3.1×10⁻⁸ 0.30 0.02 2:0:42752773:G:A A rs185250851 Intronic 0.02 2.1×10⁻⁸ 0.30 0.05 2:0:45230137.C:T^b T rs78618809 Intergenic 0.02 5.9×10⁻⁸ 0.51</td><td>8:117258547:C:Tb T rs542965166 Intronic 0.001 19 × 10⁻⁶ 0.50 0.11 1 2:21074277:A:G A rs478588 30KB upstream 0.29 2.9 × 10⁻⁹ 0.03 0.01 2:21074277:A:G A rs7903146 Intronic 0.25 2.0 × 10⁻⁹ 0.03 0.01 3:123335923:A:C A rs7903146 Intronic 0.25 2.0 × 10⁻⁸ 0.03 0.01 3:12335923:A:C A rs72964564 Intronic 0.20 2.8 × 10⁻⁸ 0.03 0.01 3:126407609:A:G G rs1328056 Intronic 0.20 2.8 × 10⁻⁸ 0.03 0.06 13:96407609:A:G G rs1328056 Intronic 0.02 3.6 × 10⁻⁸ 0.33 0.06 5:10169711:T:C C rs1335160 Intronic 0.02 2.1 × 10⁻⁸ 0.30 0.05 20:43230137:C:TP T rs78618809 Intergenic 0.02 2.1 × 10⁻⁸ 0.51 0.09 20:4455447:C:A C rs78618809 Intergenic 0.02 2.1 × 10⁻⁸ 0.51<td>Fasting glucose</td><td>Pooled</td><td>SLC30A8</td><td>8:117179236:C:T</td><td>υ</td><td>rs35859536</td><td>2.5KB downstream</td><td>0.74</td><td>1.0×10^{-9}</td><td>0.03</td><td>0.01</td><td></td></td></td<>	8:117258547:C:T ^b T rs542965166 Intronic 0.001 19×10 ⁻⁶ 0.50 0.11 1 2:21074277:A:G A rs478588 30KB upstream 0.29 2.9×10 ⁻⁹ 0.03 0.01 2:21074277:A:G A rs478588 30KB upstream 0.29 2.9×10 ⁻⁹ 0.03 0.01 3:123335923:A:C A rs77903146 Intronic 0.25 2.0×10 ⁻⁸ 0.03 0.01 3:123355923:A:C A rs72964564 Intronic 0.25 2.0×10 ⁻⁸ 0.03 0.01 3:129503:A:C A rs72964564 Intronic 0.20 2.8×10 ⁻⁸ 0.03 0.01 13:96407609:A:G G rs1328056 Intronic 0.02 3.6×10 ⁻⁸ 0.03 0.01 5:0169711:F:C C rs1335160 Intergenic 0.02 3.1×10 ⁻⁸ 0.30 0.02 2:0:42752773:G:A A rs185250851 Intronic 0.02 2.1×10 ⁻⁸ 0.30 0.05 2:0:45230137.C:T ^b T rs78618809 Intergenic 0.02 5.9×10 ⁻⁸ 0.51	8:117258547:C:Tb T rs542965166 Intronic 0.001 19 × 10 ⁻⁶ 0.50 0.11 1 2:21074277:A:G A rs478588 30KB upstream 0.29 2.9 × 10 ⁻⁹ 0.03 0.01 2:21074277:A:G A rs7903146 Intronic 0.25 2.0 × 10 ⁻⁹ 0.03 0.01 3:123335923:A:C A rs7903146 Intronic 0.25 2.0 × 10 ⁻⁸ 0.03 0.01 3:12335923:A:C A rs72964564 Intronic 0.20 2.8 × 10 ⁻⁸ 0.03 0.01 3:126407609:A:G G rs1328056 Intronic 0.20 2.8 × 10 ⁻⁸ 0.03 0.06 13:96407609:A:G G rs1328056 Intronic 0.02 3.6 × 10 ⁻⁸ 0.33 0.06 5:10169711:T:C C rs1335160 Intronic 0.02 2.1 × 10 ⁻⁸ 0.30 0.05 20:43230137:C:TP T rs78618809 Intergenic 0.02 2.1 × 10 ⁻⁸ 0.51 0.09 20:4455447:C:A C rs78618809 Intergenic 0.02 2.1 × 10 ⁻⁸ 0.51 <td>Fasting glucose</td> <td>Pooled</td> <td>SLC30A8</td> <td>8:117179236:C:T</td> <td>υ</td> <td>rs35859536</td> <td>2.5KB downstream</td> <td>0.74</td> <td>1.0×10^{-9}</td> <td>0.03</td> <td>0.01</td> <td></td>	Fasting glucose	Pooled	SLC30A8	8:117179236:C:T	υ	rs35859536	2.5KB downstream	0.74	1.0×10^{-9}	0.03	0.01	
APOB 2:21074277:A:G A rs478588 30KB upstream 0.29 2:9×10 ⁻⁹ 0.03 001 TCF7L2 10:112998590:C:T T rs7903146 Intronic 0.25 2:0×10 ⁻⁹ 0.03 001 TCF7L2 10:112998590:C:T T rs7903146 Intronic 0.25 2:0×10 ⁻⁸ 0.03 001 ADCY5 3:123335923:A:C A rs72964564 Intronic 0.25 2:0×10 ⁻⁸ 0.03 001 ADCY5 3:123335923:A:C A rs72964564 Intronic 0.25 2:0×10 ⁻⁸ 0.03 001 HS/L H56773 13:96407609:A:G G rs1328056 Intronic 0.02 3:4×10 ⁻⁸ 0.03 001 Pooled PTPRT 20:42752773:G:A A rs185550851 Intronic 0.02 5:4×10 ⁻⁸ 0.30 0.03 0.05 Pooled PTPRT 20:42752773:G:A A rs185550851 Intronic 0.002 2:1×10 ⁻⁸ 0.30 0.05	2:21074277:A:G A rs478588 30KB upstream 0.29 2:9×10 ⁻⁹ 0.03 0.01 10:112998590:C:T T rs7903146 Intronic 0.25 2:0×10 ⁻⁹ 0.03 0.01 3:123355923:A:C A rs7903146 Intronic 0.25 2:0×10 ⁻⁸ 0.03 0.01 3:123355923:A:C A rs72964564 Intronic 0.25 2:0×10 ⁻⁸ 0.03 0.01 3:1296407609:A:G G rs1328056 Intronic 0.20 3:6×10 ⁻⁸ 0.03 0.01 5:10169711:F:C C rs13351160 Intergenic 0.02 3:6×10 ⁻⁸ 0.30 0.02 2:0:42752773:G:A A rs185250851 Intronic 0.02 2:1×10 ⁻⁸ 0.30 0.02 2:0:427320137.C:T ^b T rs78618809 Intergenic 0.02 5:9×10 ⁻⁶ 0.08 0.01 0.02 2:0:455447:C:A C rs53973028 44KB upstream 0.02 4.7×10 ⁻⁸ 0.31 0.09 10:4656482:GAAAT:G G rs53973028 4AKB upstream 0.02 4.5×10 ⁻⁸ 0	2:21074277:A:G A rs478588 30KB upstream 0.29 2.9 × 10 ⁻⁹ 0.03 0.01 10:112998590:C:T T rs7903146 Intronic 0.25 2.0 × 10 ⁻⁸ 0.03 0.01 3:123335923:A:C A rs7903146 Intronic 0.25 2.0 × 10 ⁻⁸ 0.03 0.01 3:12335923:A:C A rs72964564 Intronic 0.20 2.8 × 10 ⁻⁸ 0.03 0.01 3:13:96407609:A:G G rs1328056 Intronic 0.02 3.6 × 10 ⁻⁸ 0.33 0.06 5:10169711:T:C C rs13351160 Intronic 0.02 3.6 × 10 ⁻⁸ 0.30 0.02 20:42752773:G:A A rs185250851 Intronic 0.02 2.1 × 10 ⁻⁸ 0.30 0.05 20:43230137:C:Tb T rs78618809 Intergenic 0.02 4.7 × 10 ⁻⁸ 0.51 0.09 20:456482:GAAAT:G G rs775018107 ncRNA intronic 0.00 2.4 × 10 ⁻⁸ 0.51 0.09 3:118656074:T:G ^c G rs775018107 ncRNA intronic 0.01 3.3 × 10 ⁻⁸ 0				8:117258547:C:T ^b	⊢	rs542965166	Intronic	0.001	1.9×10^{-6}	0.50	0.11	rs35859536
TCF7L2 10:112998590:C:T T rs7903146 Intronic 0.25 2.0×10 ⁻⁸ 0.03 0.01 ADCY5 3:123335923:A:C A rs72964564 Intronic 0.25 2.0×10 ⁻⁸ 0.03 0.01 HS/L H5/L H56573 3:123335923:A:C A rs72964564 Intronic 0.80 2.8×10 ⁻⁸ 0.03 0.01 ADCY5 3:123335923:A:C A rs72964564 Intronic 0.80 2.8×10 ⁻⁸ 0.03 0.01 CTD-2199C04.4 5:10169711:T:C C rs13361160 Intergenic 0.45 3:1×10 ⁻⁸ 0.10 0.02 Pooled PTRT 20:42752773:G:A A rs185250851 Intronic 0.002 2:1×10 ⁻⁸ 0.30 0.05 Robol 3:79812347:C:P T rs78618809 Intergenic 0.02 5:9×10 ⁻⁶ 0.08 0.02 0.11 0.02 2:1×10 ⁻⁸ 0.51 0.09 ROBOI 3:79812347:C:P T rs78618809 Intergenic 0.02 4;7×10 ⁻⁸ 0.51 0.09 EU LINC00704, LINC00705 <td>10:112998590:C:T T rs7903146 Intronic 0.25 2.0×10⁻⁸ 0.03 0.01 3:123355923:A:C A rs72964564 Intronic 0.80 2.8×10⁻⁸ 0.03 0.01 3:12335923:A:C A rs72964564 Intronic 0.80 2.8×10⁻⁸ 0.03 0.01 13:96407609:A:G G rs1328056 Intronic 0.02 3.6×10⁻⁸ 0.33 0.06 5:10169711:T:C C rs13351160 Intergenic 0.45 3.1×10⁻⁸ 0.10 0.02 20:42752773:G:A A rs185250851 Intronic 0.02 2.1×10⁻⁸ 0.30 0.05 20:42730137.C:T^b T rs185250851 Intronic 0.02 5.1×10⁻⁸ 0.30 0.05 20:42730137.C:T^b T rs78618809 Intergenic 0.02 5.1×10⁻⁸ 0.31 0.02 10.455 20:456482:GAAAT:G G rs57973028 44KB upstream 0.99 4.7×10⁻⁸ 0.33 0.06 3:118656074:T:G G rs117592405 ncRNA intronic 0.01 3.3×10⁻⁸ <td< td=""><td>10:112998590:C:T T rs7903146 Intronic 0.25 2.0×10⁻⁸ 0.03 0.01 3:123335923:A:C A rs72964564 Intronic 0.80 2.8×10⁻⁸ 0.03 0.01 3:12335923:A:C A rs72964564 Intronic 0.80 2.8×10⁻⁸ 0.03 0.01 13:96407609:A:G G rs1328056 Intronic 0.02 3.6×10⁻⁸ 0.33 0.06 5:10169711:T:C C rs1335160 Intronic 0.02 3.6×10⁻⁸ 0.30 0.02 20:42752773:G:A A rs185250851 Intronic 0.02 2.1×10⁻⁸ 0.30 0.05 20:43230137:C:Tb T rs78618809 Intergenic 0.02 2.1×10⁻⁸ 0.51 0.09 20:456482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.7×10⁻⁸ 0.33 0.06 3:79812347:C:F G rs775018107 ncRNA intronic 0.01 3.3×10⁻⁸ 0.33 0.06 3:118656074:T:G^c G rs775018107 ncRNA intronic 0.01 3.3×10⁻⁸ 0.31 <t< td=""><td></td><td></td><td>APOB</td><td>2:21074277:A:G</td><td>∢</td><td>rs478588</td><td>30KB upstream</td><td>0.29</td><td>2.9×10^{-9}</td><td>0.03</td><td>0.01</td><td></td></t<></td></td<></td>	10:112998590:C:T T rs7903146 Intronic 0.25 2.0×10 ⁻⁸ 0.03 0.01 3:123355923:A:C A rs72964564 Intronic 0.80 2.8×10 ⁻⁸ 0.03 0.01 3:12335923:A:C A rs72964564 Intronic 0.80 2.8×10 ⁻⁸ 0.03 0.01 13:96407609:A:G G rs1328056 Intronic 0.02 3.6×10 ⁻⁸ 0.33 0.06 5:10169711:T:C C rs13351160 Intergenic 0.45 3.1×10 ⁻⁸ 0.10 0.02 20:42752773:G:A A rs185250851 Intronic 0.02 2.1×10 ⁻⁸ 0.30 0.05 20:42730137.C:T ^b T rs185250851 Intronic 0.02 5.1×10 ⁻⁸ 0.30 0.05 20:42730137.C:T ^b T rs78618809 Intergenic 0.02 5.1×10 ⁻⁸ 0.31 0.02 10.455 20:456482:GAAAT:G G rs57973028 44KB upstream 0.99 4.7×10 ⁻⁸ 0.33 0.06 3:118656074:T:G G rs117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ <td< td=""><td>10:112998590:C:T T rs7903146 Intronic 0.25 2.0×10⁻⁸ 0.03 0.01 3:123335923:A:C A rs72964564 Intronic 0.80 2.8×10⁻⁸ 0.03 0.01 3:12335923:A:C A rs72964564 Intronic 0.80 2.8×10⁻⁸ 0.03 0.01 13:96407609:A:G G rs1328056 Intronic 0.02 3.6×10⁻⁸ 0.33 0.06 5:10169711:T:C C rs1335160 Intronic 0.02 3.6×10⁻⁸ 0.30 0.02 20:42752773:G:A A rs185250851 Intronic 0.02 2.1×10⁻⁸ 0.30 0.05 20:43230137:C:Tb T rs78618809 Intergenic 0.02 2.1×10⁻⁸ 0.51 0.09 20:456482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.7×10⁻⁸ 0.33 0.06 3:79812347:C:F G rs775018107 ncRNA intronic 0.01 3.3×10⁻⁸ 0.33 0.06 3:118656074:T:G^c G rs775018107 ncRNA intronic 0.01 3.3×10⁻⁸ 0.31 <t< td=""><td></td><td></td><td>APOB</td><td>2:21074277:A:G</td><td>∢</td><td>rs478588</td><td>30KB upstream</td><td>0.29</td><td>2.9×10^{-9}</td><td>0.03</td><td>0.01</td><td></td></t<></td></td<>	10:112998590:C:T T rs7903146 Intronic 0.25 2.0×10 ⁻⁸ 0.03 0.01 3:123335923:A:C A rs72964564 Intronic 0.80 2.8×10 ⁻⁸ 0.03 0.01 3:12335923:A:C A rs72964564 Intronic 0.80 2.8×10 ⁻⁸ 0.03 0.01 13:96407609:A:G G rs1328056 Intronic 0.02 3.6×10 ⁻⁸ 0.33 0.06 5:10169711:T:C C rs1335160 Intronic 0.02 3.6×10 ⁻⁸ 0.30 0.02 20:42752773:G:A A rs185250851 Intronic 0.02 2.1×10 ⁻⁸ 0.30 0.05 20:43230137:C:Tb T rs78618809 Intergenic 0.02 2.1×10 ⁻⁸ 0.51 0.09 20:456482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.7×10 ⁻⁸ 0.33 0.06 3:79812347:C:F G rs775018107 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.33 0.06 3:118656074:T:G ^c G rs775018107 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.31 <t< td=""><td></td><td></td><td>APOB</td><td>2:21074277:A:G</td><td>∢</td><td>rs478588</td><td>30KB upstream</td><td>0.29</td><td>2.9×10^{-9}</td><td>0.03</td><td>0.01</td><td></td></t<>			APOB	2:21074277:A:G	∢	rs478588	30KB upstream	0.29	2.9×10^{-9}	0.03	0.01	
ADCY5 3:123335923:A:C A rs72964564 Intronic 0.80 2.8×10 ⁻⁸ 0.03 0.01 HS/L H56573 13:96407609;A:G G rs1328056 Intronic 0.80 2.8×10 ⁻⁸ 0.03 0.01 CTD-2199C04.4 5:10169711;T.C C rs13361160 Intensic 0.02 3.6×10 ⁻⁸ 0.10 0.02 Pooled PTPRT 20:42752773:G:A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.10 0.02 Pooled PTPRT 20:42752773:G:A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.05 Pooled PTPRT 20:43230137:C:T ^b T rs78618809 Intergenic 0.02 5.9×10 ⁻⁶ 0.08 0.02 1 ROBOI 3:79812347:C:T ^b T rs78618809 Intergenic 0.099 4.7×10 ⁻⁸ 0.51 0.099 EU LINC00704, LINC00705 10:4656482:GAAAAT:G G rs775018107 ncRNA intronic 0.002 4.5×10 ⁻⁸ 0.33 0.06 Samoan RPI1/IGSF11 3:11	3:12335923:A:C A rs72964564 Intronic 0.80 2.8×10 ⁻⁸ 0.03 0.01 13:96407609:A:G G rs1328056 Intronic 0.02 3.6×10 ⁻⁸ 0.33 0.06 5:10169711:T:C C rs1328056 Intronic 0.02 3.6×10 ⁻⁸ 0.33 0.06 5:10169711:T:C C rs13361160 Intronic 0.02 3.6×10 ⁻⁸ 0.30 0.02 20:42752773:G:A A rs185250851 Intronic 0.02 2.1×10 ⁻⁸ 0.30 0.05 20:423230137:C:T ^b T rs78618809 Intergenic 0.02 5.9×10 ⁻⁶ 0.08 0.02 1 20:432347:C:A C rs578618809 Intergenic 0.02 4.7×10 ⁻⁸ 0.51 0.09 3:79812347:C:A C rs539973028 44KB upstream 0.99 4.7×10 ⁻⁸ 0.51 0.09 3:79812347:C:A G rs5775018107 ncRNA intronic 0.002 4.5×10 ⁻⁸ 0.33 0.06 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0	3:12335923:A.C A rs72964564 Intronic 0.80 2.8 × 10 ⁻⁸ 0.03 0.01 13:96407609:A:G G rs1328056 Intronic 0.02 3.6 × 10 ⁻⁸ 0.33 0.06 5:10169711:T:C C rs1328056 Intronic 0.02 3.6 × 10 ⁻⁸ 0.33 0.06 5:10169711:T:C C rs13361160 Intronic 0.02 3.6 × 10 ⁻⁸ 0.30 0.05 20:42752773:G:A A rs185250851 Intronic 0.002 2.1 × 10 ⁻⁸ 0.30 0.05 20:43230137:C:T ^b T rs78618809 Intergenic 0.02 5.9 × 10 ⁻⁶ 0.08 0.02 10 20:455487:C:T ^b T rs78618809 Intergenic 0.002 2.1 × 10 ⁻⁸ 0.51 0.09 3:79812347:C:A C rs775018107 ncRNA intronic 0.002 4.7 × 10 ⁻⁸ 0.33 0.06 3:118656074:T:G ^c G rs7775018107 ncRNA intronic 0.01 3.3 × 10 ⁻⁸ 0.33 0.06 3:118656074:T:G ^c G rs717592405 ncRNA intronic 0.01			TCF7L2	10:112998590:C:T	⊢	rs7903146	Intronic	0.25	2.0×10^{-8}	0.03	0.01	
HS/L H56573 13:96407609;A:G G rs1328056 Intronic 0.02 3.6×10 ⁻⁸ 0.33 0.06 CTD-2199C04.4 5:10169711;T.C C rs13361160 Intergenic 0.45 3.1×10 ⁻⁸ 0.10 0.02 Pooled PTPRT 20:42752773:G:A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.10 0.02 Pooled PTPRT 20:42752773:G:A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.05 Pooled PTPRT 20:43230137:C:T ^b T rs78618809 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.02 1 ROBOI 3:79812347:C:T ^b T rs78618809 Intergenic 0.09 4.7×10 ⁻⁸ 0.51 0.09 EU LINCO0704, LINCO0705 10:4656482:GAAAAT:G G rs775018107 ncRNA intronic 0.002 4.5×10 ⁻⁸ 0.33 0.06 Samoan RP11/IGSF11 3:117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ </td <td>13:96407609:A:G G rs1328056 Intronic 0.02 3.6 × 10⁻⁸ 0.33 0.06 5:10169711:T:C C rs13361160 Intergenic 0.45 3.1 × 10⁻⁸ 0.10 0.02 20:42752773:G:A A rs185250851 Intronic 0.02 2.1 × 10⁻⁸ 0.10 0.02 20:42752773:G:A A rs185250851 Intronic 0.002 2.1 × 10⁻⁸ 0.30 0.05 20:423230137:C:T^b T rs78618809 Intergenic 0.02 5.9 × 10⁻⁶ 0.08 0.02 1 20:4456482:GAAAAT:G G rs775018107 ncRNA intronic 0.002 4.5 × 10⁻⁸ 0.51 0.09 3:118656074:T:G^c G rs117592405 ncRNA intronic 0.01 3.3 × 10⁻⁸ 0.30 0.14</td> <td>13:96407609:A:G G rs1328056 Intronic 0.02 3.6 × 10⁻⁸ 0.33 0.06 5:10169711:T:C C rs13361160 Intergenic 0.45 3.1 × 10⁻⁸ 0.10 0.02 20:42752773:G:A A rs185250851 Intronic 0.002 2.1 × 10⁻⁸ 0.30 0.05 20:42752773:G:A A rs185250851 Intronic 0.002 2.1 × 10⁻⁸ 0.30 0.05 20:43230137:C:Tb T rs78618809 Intergenic 0.02 5.9 × 10⁻⁶ 0.08 0.02 1 3:79812347:C:A C rs539973028 44KB upstream 0.99 4.7 × 10⁻⁸ 0.51 0.09 10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.001 3.3 × 10⁻⁸ 0.33 0.06 3:118656074:T:G^c G rs117592405 ncRNA intronic 0.01 3.3 × 10⁻⁸ 0.33 0.06 warant with the lowest P-value and lighest posterior probability representing a distinct association at a locus. 0.01 3.3 × 10⁻⁸ 0.14</td> <td></td> <td></td> <td>ADCY5</td> <td>3:123335923:A:C</td> <td>∢</td> <td>rs72964564</td> <td>Intronic</td> <td>0.80</td> <td>2.8×10^{-8}</td> <td>0.03</td> <td>0.01</td> <td></td>	13:96407609:A:G G rs1328056 Intronic 0.02 3.6 × 10 ⁻⁸ 0.33 0.06 5:10169711:T:C C rs13361160 Intergenic 0.45 3.1 × 10 ⁻⁸ 0.10 0.02 20:42752773:G:A A rs185250851 Intronic 0.02 2.1 × 10 ⁻⁸ 0.10 0.02 20:42752773:G:A A rs185250851 Intronic 0.002 2.1 × 10 ⁻⁸ 0.30 0.05 20:423230137:C:T ^b T rs78618809 Intergenic 0.02 5.9 × 10 ⁻⁶ 0.08 0.02 1 20:4456482:GAAAAT:G G rs775018107 ncRNA intronic 0.002 4.5 × 10 ⁻⁸ 0.51 0.09 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3 × 10 ⁻⁸ 0.30 0.14	13:96407609:A:G G rs1328056 Intronic 0.02 3.6 × 10 ⁻⁸ 0.33 0.06 5:10169711:T:C C rs13361160 Intergenic 0.45 3.1 × 10 ⁻⁸ 0.10 0.02 20:42752773:G:A A rs185250851 Intronic 0.002 2.1 × 10 ⁻⁸ 0.30 0.05 20:42752773:G:A A rs185250851 Intronic 0.002 2.1 × 10 ⁻⁸ 0.30 0.05 20:43230137:C:Tb T rs78618809 Intergenic 0.02 5.9 × 10 ⁻⁶ 0.08 0.02 1 3:79812347:C:A C rs539973028 44KB upstream 0.99 4.7 × 10 ⁻⁸ 0.51 0.09 10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.001 3.3 × 10 ⁻⁸ 0.33 0.06 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3 × 10 ⁻⁸ 0.33 0.06 warant with the lowest P-value and lighest posterior probability representing a distinct association at a locus. 0.01 3.3 × 10 ⁻⁸ 0.14			ADCY5	3:123335923:A:C	∢	rs72964564	Intronic	0.80	2.8×10^{-8}	0.03	0.01	
CTD-2199C04.4 5:10169711:T.C C rs13361160 Intergenic 0.45 3.1×10 ⁻⁸ 0.10 0.02 Pooled PTPRT 20:42752773:G.A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.05 Pooled PTPRT 20:42752773:G.A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.05 ROBO1 20:43230137:C:T ^b T rs78618809 Intergenic 0.02 5.9×10 ⁻⁶ 0.08 0.02 1 ROBO1 3:79812347:C:A C rs539973028 44KB upstream 0.99 4.7×10 ⁻⁸ 0.51 0.09 EU LINC00704, LINC00705 10:4656482:GAAAAT:G G rs775018107 ncRNA intronic 0.002 4.5×10 ⁻⁸ 0.33 0.06 Samoan RP11/IGSF11 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.80 0.14	5:10169711;T:C C rs13361160 Intergenic 0.45 3.1×10 ⁻⁸ 0.10 0.02 20:42752773;G:A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.05 20:42752773;G:A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.05 20:423230137;C:T ^b T rs78618809 Intergenic 0.02 5.9×10 ⁻⁶ 0.08 0.02 1 3:79812347;C:A C rs539973028 44KB upstream 0.99 4.7×10 ⁻⁸ 0.51 0.09 10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.5×10 ⁻⁸ 0.33 0.06 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.80 0.14	5:10169711;T:C C rs13361160 Intergenic 0.45 3.1×10 ⁻⁸ 0.10 0.02 20:42752773;G:A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.05 20:42752773;G:A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.05 20:43230137:C:T ^b T rs78618809 Intergenic 0.02 5.9×10 ⁻⁶ 0.08 0.02 10 3:79812347:C:A C rs539973028 44KB upstream 0.99 4.7×10 ⁻⁸ 0.51 0.09 10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.5×10 ⁻⁸ 0.33 0.06 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.80 0.14 variant with the lowest P-value and highest posterior probability representing a distinct association at a locus. 0.01 3.3×10 ⁻⁸ 0.80 0.14 MAC > 20 after conditional analysis. 20 after conditional analysis. 3.117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.08 0.14		HS/L	HS6ST3	13:96407609:A:G	IJ	rs1328056	Intronic	0.02	3.6×10^{-8}	0.33	0.06	
Pooled PTPRT 20:42752773:G:A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.05 Pooled PTPRT 20:43230137:C:T ^b T rs78618809 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.02 r ROBO1 20:43230137:C:T ^b T rs78618809 Intergenic 0.02 5.9×10 ⁻⁶ 0.08 0.02 r ROBO1 3:79812347:C:A C rs539973028 44KB upstream 0.99 4.7×10 ⁻⁸ 0.51 0.09 EU LINC00704, LINC00705 10:4656482:GAAAAT:G G rs775018107 ncRNA intronic 0.002 4.5×10 ⁻⁸ 0.33 0.06 Samoan RP11/IGSF11 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.80 0.14	20:42752773:G:A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.05 20:43230137:C:T ^b T rs78618809 Intergenic 0.02 5.9×10 ⁻⁶ 0.08 0.02 r 3:79812347:C:A C rs539973028 44KB upstream 0.99 4.7×10 ⁻⁸ 0.51 0.09 10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.5×10 ⁻⁸ 0.33 0.06 3:118656074:T:G ^c G rs17592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.80 0.14	20:42752773:G:A A rs185250851 Intronic 0.002 2.1×10 ⁻⁸ 0.30 0.05 20:43230137:C:Tb T rs78618809 Intergenic 0.02 5.9×10 ⁻⁶ 0.08 0.02 1 3:79812347:C:A C rs539973028 44KB upstream 0.99 4.7×10 ⁻⁸ 0.51 0.09 10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.5×10 ⁻⁸ 0.33 0.06 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.80 0.14 variant with the lowest P-value and highest posterior probability representing a distinct association at a locus. 0.01 3.3×10 ⁻⁸ 0.80 0.14			CTD-2199C04.4	5:10169711:T:C	U	rs13361160	Intergenic	0.45	3.1×10^{-8}	0.10	0.02	
20:43230137.C:T ^b T rs78618809 Intergenic 0.02 5.9×10 ⁻⁶ 0.08 0.02 1 ROBO1 3:79812347.C:A C rs539973028 44KB upstream 0.99 4.7×10 ⁻⁸ 0.51 0.09 EU LINC00704, LINC00705 10:4656482:GAAAAT:G G rs775018107 ncRNA intronic 0.002 4.5×10 ⁻⁸ 0.33 0.06 Samoan RP11/IG5F11 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.80 0.14	20:43230137:C:T ^b T rs78618809 Intergenic 0.02 5.9×10 ⁻⁶ 0.08 0.02 n 3:79812347:C:A C rs539973028 44KB upstream 0.99 4.7×10 ⁻⁸ 0.51 0.09 10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.5×10 ⁻⁸ 0.33 0.06 3:118656074:T:G ^c G rs17592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.80 0.14	20:43230137:C:Tb T rs78618809 Intergenic 0.02 5.9×10 ⁻⁶ 0.08 0.02 1 3:79812347:C:A C rs539973028 44KB upstream 0.99 4.7×10 ⁻⁸ 0.51 0.09 10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.5×10 ⁻⁸ 0.33 0.06 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.80 0.14 variant with the lowest P-value and highest posterior probability representing a distinct association at a locus. 0.01 3.3×10 ⁻⁸ 0.80 0.14	Fasting	Pooled	PTPRT	20:42752773:G:A	∢	rs185250851	Intronic	0.002	2.1×10^{-8}	0.30	0.05	
ROBO1 3:79812347.C:A C rs539973028 44KB upstream 0.99 4.7 × 10 ⁻⁸ 0.51 (LINCO0704, LINCO0705 10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.5 × 10 ⁻⁸ 0.33 (RP11/165F11 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3 × 10 ⁻⁸ 0.80 (3:79812347.C.A C rs539973028 44KB upstream 0.99 4.7 × 10 ⁻⁸ 0.51 (10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.5 × 10 ⁻⁸ 0.33 (3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3 × 10 ⁻⁸ 0.80 (3:79812347.C:A C rs539973028 44KB upstream 0.99 4.7 × 10 ⁻⁸ 0.51 0 10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.5 × 10 ⁻⁸ 0.33 0 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3 × 10 ⁻⁸ 0.80 0 variant with the lowest <i>P-value</i> and highest posterior probability representing a distinct association at a locus. MAC > 20 after conditional analysis.	insulin			20:43230137:C:T ^b	⊢	rs78618809	Intergenic	0.02	5.9×10^{-6}	0.08	0.02	rs185250851
LINCO0704, LINCO0705 10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.5 × 10 ⁻⁸ 0.33 (RP11/IG5F11 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3 × 10 ⁻⁸ 0.80 (10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.5 × 10 ⁻⁸ 0.33 (3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3 × 10 ⁻⁸ 0.80 (10:4656482:GAAAT:G G rs775018107 ncRNA intronic 0.002 4.5 × 10 ⁻⁸ 0.33 (3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3 × 10 ⁻⁸ 0.80 (variant with the lowest P-value and highest posterior probability representing a distinct association at a locus. MAC > 20 after conditional analysis.			ROBO1	3:79812347:C:A	U	rs539973028	44KB upstream	0.99	4.7×10^{-8}	0.51	0.09	
<i>RP11/IG5F11</i> 3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.80 (3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3×10 ⁻⁸ 0.80 (3:118656074:T:G ^c G rs117592405 ncRNA intronic 0.01 3.3 × 10 ⁻⁸ 0.80 C variant with the lowest <i>P</i> -value and highest posterior probability representing a distinct association at a locus.		EU	LINCO0704, LINC00705	10:4656482:GAAAAT:G	IJ	rs775018107	ncRNA intronic	0.002	4.5×10^{-8}	0.33	0.06	
	EA effect allele, EAF effect allele frequency, EU European, HS/L Hispanic/Latinx.	E effect allele <i>f</i> -F effect allele frequency. <i>EU</i> European, <i>HS/L</i> Hispanic/Latinx. ^a Chromosome, position(Hg38), reference allele, alternative allele of the genetic variant with the lowest <i>P-</i> value and highest posterior probability representing a distinct association at a locus. ^b Indicates secondary signal for association at significance level <i>P</i> -(1 × 10 ⁻⁵ and MAC > 20 after conditional analysis.		Samoan	RP11/IGSF11	3:118656074:T:G ^c	U	rs117592405	ncRNA intronic	0.01	3.3×10^{-8}	0.80	0.14	

This multi-ethnic WGS study provides the foundation for future sequencing-based investigation of glycemic traits. Our results from common and rare variant analysis comprised multiple suggestive hits, including those with exceedingly rare variants that require further investigation, indicating the potential for the identification of novel signals given larger sequencing studies and external validation studies. The value of diverse studies like TOPMed is further evidenced by the specificity of such signals to certain populations and cohorts. This value is also demonstrated by the intronic and intergenic location of many such suggested signals. These signals, in both single variant and rare variant set-based testing, indicated that many associations lie outside gene boundaries and it is important to perform genomewide single variant testing but also complement gene-centric RV testing with region-based RV testing to fully capture signal. Future TOPMed study phases will permit the continued investigation of these signals empowered by increased sample sizes, with future directions including detailed fine-mapping of signal regions and assessment of glycemic trait heritability. To support future research, all results from this analysis have been made available to the research community through the Type 2 Diabetes Knowledge Portal (Genetic Association Data will be released in January 2021)¹⁷.

Methods

Whole-genome sequencing. Whole-genome sequencing of blood samples for all participants included deep coverage (>30x on average) sequencing from blood samples provided by the NHLBI TOPMed program. Sequencing was performed across six centers (Broad Institute of MIT and Harvard, Northwest Genomics Center, New York Genome Center, Illumina Genomic Services, Macrogen, and Baylor College of Medicine Human Genome Sequencing Center) as previously described³⁵. The TOPMed Informatics Research Center at the University of Michigan performed data harmonization and joint variant discovery and genotype calling, requiring DNA sample contamination below 3% and at least 95% of the genome with at least 10x coverage. Freeze 5b was aligned to GRCh38 reads from the 1000 Genomes Project reference sequences³⁶. The samples were further processed by a centralized pipeline by the TOPMed Data Coordinating Center at the University of Washington, where further quality control and sample-identity resolution were performed, including sex and relatedness concordance and selection of variants with missingness <5% and QUAL > 127. Variants were also checked via an excess heterozygosity filter (EXHET), which removed the variant if the Hardy-Weinberg disequilibrium p-value was $<1 \times 10^{-6}$, after accounting for population structure. After processing, Freeze 5b contained 54,508 samples with 438 million single nucleotide variants (SNVs) and 33 million short insertiondeletion variants.

Population structure principal components were calculated across all Freeze 5b TOPMed participants using PC-AiR; a genetic relatedness matrix was calculated across all Freeze 5b TOPMed participants using PC-Relate accounting for population structure. Race/ethnicity was determined by self-report from each study. Self-reported race/ethnicity was used in conjunction with principal component and/or genetic relatedness matrix adjustment to control for both genetic and individually identified ancestry³⁷.

Phenotype harmonization. Phenotype harmonization proceeded following a protocol defined by the TOPMed Diabetes Working Group for participating TOPMed studies. Duplicated individuals were excluded following the TOPMed Diabetes Working Group protocol. Within a study, monozygotic twins were retained and the duplicate to be kept was chosen based on verification of cohort characteristics, including proper cohort sequencing center designation, and then by highest call rate. Across studies, duplicates were selected by removing missing trait data, prioritizing population-based cohorts, and retaining individual records with the longest follow-up period. All study participants provided informed consent and each study was approved by their respective institutional review boards.

Glycemic traits (fasting glucose (FG) and fasting insulin (FI)) were analyzed for individuals who did not have diabetes at the time of glycemic trait measurement. This subset was defined as those not taking anti-diabetes medication, with fasting glucose <7 mmol/l and/or HbA1c < 6.5%. For individuals with multiple blood draws, the earliest exam or most complete exam was used. Age, sex, and BMI covariates were reported at the time of glycemic trait measurement. Fasting was defined to be at least 8 h without food or drink; measurements from blood were converted to plasma values using a 1.13 correction factor³⁸. The units for glucose are mmol/l; units for insulin are pmol/l. Fasting insulin was natural logtransformed prior to analysis in order to address non-normality. **Study sample and power**. The present analysis included 23,211 (FI) and 26,807 (FG) individuals from the NHLBI TOPMed program. The cohorts included consist of participants of self-reported African American (FI n = 6803; FG n = 7174), East Asian (FI n = 572; FG n = 2217), European (FI n = 13,281; FG n = 14,513), Hispanic/Latinx (FI n = 1641; FG n = 1989), and Samoan (FI n = 914; FG n = 914) race/ethnicity. Our analysis of fasting insulin included 14 cohorts and fasting glucose included 15 cohorts. The sample is predominantly of European race/ethnicity (FI 57.2%; FG 54.1%) and female (FI 66.5%; FG 65.2%); full cohort descriptions are given in Supplementary Tables 2 and 3.

We performed a post hoc power calculation to evaluate the power to detect genetic signal at the genome-wide threshold for statistical significance of 5×10^{-8} . Given the study sample size, this analysis was powered to detect 0.54–4.21% and 0.57–4.21% percent variation in glycemic trait explained by a genotype in race/ ethnicity-specific analyses for FG and FI, respectively. The pooled study including all samples was powered to detect 0.16% and 0.17% percent variation in glycemic trait explained by a genotype for FG and FI, respectively.

Single-variant analysis. We performed single variant analysis in Freeze 5b of TOPMed using race/ethnicity-specific and pooled approaches. We tested 64,675,008 variants for associations with FG and 58,759,883 with FI in both pooled and race/ethnicity-specific analyses, and restricted analysis to variants with minor allele count >= 20. We used linear mixed effects models and adjusted for age, age squared, sex, body mass index, study-race/ethnicity, with heterogeneous variance permitted across study-race/ethnicity groups and empirical kinship for relatedness and population structure. Models were fit using GENetic Estimation and Inference in Structured samples (GENESIS)³⁹ in the Analysis Commons cloud-computing platform⁴⁰. *P*-Values reported are for a two-sided Wald test from the mixed model. Fasting glucose and natural log-transformed fasting insulin were used as outcomes in separate models. We define the standard genome-wide threshold for statistical significance as 1×10^{-9} . We also report variants with $P < 5 \times 10^{-8}$ as suggestively associated to provide context for regions of interest for future, higher-powered studies.

Stepwise conditional analysis was performed at each identified locus, defined to be a 500 kb region centered on the most significant variant, in order to identify distinct signals. This analysis proceeded by first including the most significant variant as a covariate, and repeating until no variants were associated with the phenotype with *p*-value <1 × 10⁻⁵. For each distinct signal, a final model was run conditioning on the set of other distinct signals; we report these potentially distinct signals.

Towards fine-mapping the identified loci, we generated 95% credible sets to investigate likely causal variants (LocalZoom). For each locus, we calculated Bayes factors for all variants from their single variant p-value; p-values were taken from conditional analyses on all other identified variants at the locus where multiple distinct signals were identified in the stepwise conditional analysis. We calculated posterior probability of association (PP) of each variant as the proportion contributed to the summation of all BFs in the region. The variants were sorted by descending PP, indicating decreasing probability that the variant is truly associated with the glycemic trait. The 95% credible set was constructed by including variants, starting with the highest PPA, until their cumulative PPA exceeded 0.95. 99% credible sets were similarly constructed for association signals from the pooled analysis only.

Rare variant analysis. We performed gene-based and genetic region aggregate testing to identify sets of rare variants associated with fasting glucose and log-transformed fasting insulin. We first fit a heteroscedastic linear mixed model for fasting glucose and log-transformed fasting insulin. Both traits were adjusted for age, age², sex, body mass index (BMI), study-race/ethnicity group indicators, and ten population structure principal components. A variance component was included for the empirically derived sparse kinship matrix and residual variances were permitted to be different for study-race/ethnicity groups to account for family relatedness, population structure, and study-race/ethnicity differences.

The heteroscedastic linear mixed model was used to perform variant set analyses for rare variants with MAF < 1%. Sets were defined by genetic regions and gene-centric categories. Genetic regions allowed the complete analysis of the genome, particularly non-coding regions that have not been previously captured by arrays. The regional analysis used 2 kb sliding windows to scan the genome with 1 kb skip length. The gene-centric analysis examined all protein-coding genes in Ensembl using functionally determined masks to aggregate variants together by coding and non-coding annotations. Coding annotations were used to define three SNV filters categorized by GENCODE based on consequence: (a) putative loss of function (stop gain, stop loss, splicing), (b) missense, and (c) synonymous variants. Leveraging the whole-genome sequencing, we used non-coding annotations to test sets of variants that are not protein coding. We constructed masks (d) characterized as promoters given they were within +/-3 kb of a transcription start site with CAGE signal overlay, or (e) characterized as enhancers given they were identified by GeneHancer with CAGE signal overlay.

The burden test and SKAT were used for testing the association of the rare variant sets and FG and FI. In these approaches, a weight based on the MAF can be used to upweight rarer variants. We considered two common weighting schemes based on $w_j = \text{Beta}(\text{MAF}_j; a_1, a_2)$, where $a_1 = 1$ and $a_2 = 25$ or $a_1 = 1$ and $a_2 = 1$.

Statistical significance was defined for each glycemic trait, separately for genecentric and genetic region analysis. For gene-centric analysis, a threshold was defined by a Bonferroni-corrected significance threshold of $\alpha \approx 0.05/(120,000) = 4 \times 10^{-7}$, correcting for all five masks and all protein-coding genes when considering the minimum *p*-value across the burden and SKAT tests (Supplementary Table 9). The threshold for the genetic region analysis was determined given the total number of 2 kb sliding windows tested, yielding a Bonferroni-corrected threshold of $\alpha \approx 0.05/(2.68 \times 10^6) = 1.86 \times 10^{-8}$. We report sets that include variant(s) with effective minor allele count greater than five and that are not exclusively composed of singletons; complete results based on the significance threshold are provided in Supplementary Data 6–9.

Haplotype analysis. We performed haplotype analysis for variants associated with fasting glucose. This analysis considered a set of 18,071 unrelated individuals, identified by PC-AiR⁴¹ by the TOPMed Program with a threshold of third-degree relatives. We performed regression of fasting glucose on haplotype using a two-step EM algorithm on the unphased genotypes, as implemented in the haplo.stats R package⁴². The posterior probabilities of haplotypes were computed for variants in the *G6PC2* gene; the variants were included based on the variants included in a previous *G6PC2* haplotype analysis, variants driving the *G6PC2* missense set signal, and distinct *G6PC2* signals from the single variant analysis. The association was adjusted for age, age², sex, body mass index, study-race/ethnicity, and ten population structure principal components.

Annotation. In order to characterize the functional impact of associated variants, we assembled functional annotations from multiple publicly available databases. We considered annotations from the Diabetes Epigenome Atlas, FAVOR, InsPIRE, and GTEx projects. From the Diabetes Epigenome Atlas, we obtained chromatin states from four tissues relevant to glycemic traits: adipose, islet, liver, and muscle. These were available from two experiments, Parker lab ChromHMM 13-state model under accession TSTSR679993 & AMP-T2D ChromHMM 18-state model under accession TSTSR043890. We also report annotation PCs from the FAVOR database⁴³, which are summaries calculated as the first principal component of individual functional annotations across functional categories including conservation, epigenetics, local nucleotide diversity, mutation density, protein function, proximity to TSS/TSE, proximity to coding, and transcription factor binding. The individual annotations contributing to the aPCs are previously described¹⁴ Annotation PCs are calculated at the variant level and reported as PHRED-scaled scores derived from the first PC from the category's PCA, providing the interpretation that variants with scores >10 are in the top 10% of category across all TOPMed variants. We obtained pancreatic islet-specific signals from the InsPIRE consortium and tissue-specific signals from the GTEx project (Version 8) to assess colocalization with gene expression at signal variants and those highly linked to signal variants via look-up. We reported eQTLs in the following tissues, reported for their importance in glycemic phenotypes: adipose subcutaneous, adipose visceral, muscle skeletal, and pancreas.

Replication. We sought to replicate our findings in the METSIM study⁴⁴, using data from 10,058 individuals with fasting glucose, fasting insulin, and TOPMed-imputed genotypes. EMMAX was used to test for associations with fasting glucose or log-transformed fasting insulin at the variants reported in Table 1 with age, age², and BMI as covariates and kinship; sex was not included as a covariate as the study is all males.

We additionally performed replication analysis in a sample from the UK Biobank. A sample of 12,854 European ancestry individuals from the UK Biobank with glucose was selected from all individuals with glucose measurement, excluding individuals with diabetes (Data-field 2443), on diabetes medication (Data-field 6177/6153), or with fasting time <8 h (Data-field 74). Glucose values were taken from variable 30740. The model included age (Data-field 21022), age², sex (Datafield 31), BMI (Data-field 21001), and ten population structure PCs. Association models were run using Scalable and Accurate Implementation of GEneralized mixed model (SAIGE)⁴⁵ to analyze UKBB phenotype data and the imputed chip genetic data.

This research has been conducted using the UK Biobank Resource under Application Number 42614.

We also performed replication analysis of the Samoan-specific association of rs117592405 with fasting insulin in a cohort of 1401 Samoans without WGS from the Samoan Study. rs117592405 was imputed using a Samoan-specific reference panel that was developed from the WGS of 1284 Samoans as part of TOPMed. R version 3.6.0 was used to replicate the association with fasting insulin in individuals without a previous diabetes diagnosis or diabetes medication use. Age, age², BMI, and sex were included in the model.

Enrichment. The tool GREGOR was used to assess if our trait-associated variants in Table 1 were significantly enriched in a particular chromatin state annotation. Using computed LD from the 1000-genomes reference panel and the 18-state chromatin model described in the text and shown in Fig. 1, we obtained an

expected number of variants to lie within each chromatin state. This was compared to the observed number of variants in each chromatin state to generate a P-value. Any P-values <0.05 are reported in the text and Supplementary Table 8.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The summary results generated during this study are available at the AMP-T2D Portal, http://t2d.hugeamp.org/. Fasting Insulin: https://t2d.hugeamp.org/dinspector.html? dataset=TOPMed_frz5b_pooled_FI_WGS. Fasting Glucose: https://t2d.hugeamp.org/ dinspector.html?dataset=TOPMed_frz5b_pooled_FG_WGS. Accession codes for genotype and phenotype files by cohort may be found in Supplementary Table 1.

Code availability

This study did not rely on custom code or mathematical algorithms.

Received: 6 October 2021; Accepted: 12 July 2022; Published online: 28 July 2022

References

- Saeedi, P. et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. *Diabetes Res. Clin. Pr.* 157, 107843 (2019).
- Wessel, J. et al. Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. *Nat. Commun.* 6, 5897 (2015).
- Mahajan, A. et al. Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus. *PLoS Genet.* 11, e1004876 (2015).
- Jun, G. et al. Evaluating the contribution of rare variants to type 2 diabetes and related traits using pedigrees. *Proc. Natl Acad. Sci. USA* 115, 379–384 (2018).
- 5. Manning, A. et al. A low-frequency inactivating AKT2 variant enriched in the finnish population is associated with fasting insulin levels and type 2. *Diabetes Risk. Diabetes* **66**, 2019–2032 (2017).
- Ng, N. H. J. et al. Tissue-specific alteration of metabolic pathways influences glycemic regulation. https://www.biorxiv.org/content/10.1101/790618v1 (2020).
- Sarnowski, C. et al. Impact of rare and common genetic variants on diabetes diagnosis by hemoglobin A1c in multi-ancestry cohorts: the trans-omics for precision medicine program. Am. J. Hum. Genet. 105, 706–718 (2019).
- Manning, A. K. et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. *Nat. Genet.* 44, 659–669 (2012).
- 9. Dupuis, J. et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat. Genet.* **42**, 105–116 (2010).
- Fuchsberger, C. et al. The genetic architecture of type 2 diabetes. Nature 536, 41-47 (2016).
- Pulit, S. L., de With, S. A. & de Bakker, P. I. Resetting the bar: statistical significance in whole-genome sequencing-based association studies of global populations. *Genet. Epidemiol.* 41, 145–151 (2017).
- Chen, J. et al. The trans-ancestral genomic architecture of glycemic traits. *Nat. Genet.* 53, 840–860 (2021).
- Pessentheiner, A. R., Ducasa, G. M. & Gordts, P. Proteoglycans in obesityassociated metabolic dysfunction and meta-inflammation. *Front. Immunol.* 11, 769 (2020).
- 14. Zhu, L. et al. Eosinophil inversely associates with type 2 diabetes and insulin resistance in Chinese adults. *PLoS ONE* **8**, e67613 (2013).
- Schmidt, E. M. et al. GREGOR: evaluating global enrichment of traitassociated variants in epigenomic features using a systematic, data-driven approach. *Bioinformatics* 31, 2601–2606 (2015).
- Viñuela, A. et al. Genetic variant effects on gene expression in human pancreatic islets and their implications for T2D. *Nat. Commun.* 11, 4912 (2020).
- Type 2 Diabetes Knowledge Portal. *Genetic Association Data Sets.* type2diabetesgenetics.org. https://t2d.hugeamp.org/datasets.html (2020).
- Chen, J., Spracklen, C. N., Marenne, G. & Varshney, A. The trans-ancestral genomic architecture of glycaemic traits. https://www.biorxiv.org/content/10. 1101/2020.07.23.217646v1 (2020).
- Li, X. et al. Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. *Nat. Genet.* 52, 969–983 (2020).

- Pena, G. G., Dutra, M. S., Gazzinelli, A., Correa-Oliveira, R. & Velasquez-Melendez, G. Heritability of phenotypes associated with glucose homeostasis and adiposity in a rural area of Brazil. *Ann. Hum. Genet.* **78**, 40–49 (2014).
- Gervais, O. et al. Genomic heritabilities and correlations of 17 traits related to obesity and associated conditions in the Japanese population. G3 (Bethesda) 10, 2221–2228 (2020).
- Richardson, T. G. et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. *PLoS Med.* 17, e1003062 (2020).
- 23. Wessel, J. et al. Rare non-coding variation identified by large scale whole genome sequencing reveals unexplained heritability of type 2 diabetes. Preprint at *medRxiv* https://doi.org/10.1101/2020.11.13.20221812 (2020).
- 24. Nagy, R. et al. Exploration of haplotype research consortium imputation for genome-wide association studies in 20,032 Generation Scotland participants. *Genome Med.* **9**, 23 (2017).
- Ramos-Rodríguez, M. et al. The impact of proinflammatory cytokines on the β-cell regulatory landscape provides insights into the genetics of type 1 diabetes. *Nat. Genet.* 51, 1588–1595 (2019).
- Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 581, 434–443 (2020).
- Zhou, W. et al. The expression of the Slit-Robo signal in the retina of diabetic rats and the vitreous or fibrovascular retinal membranes of patients with proliferative diabetic retinopathy. *PLoS ONE* 12, e0185795 (2017).
- Pulit, S. L. et al. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum. Mol. Genet.* 28, 166–174 (2019).
- 29. Kichaev, G. et al. Leveraging polygenic functional enrichment to improve GWAS power. *Am. J. Hum. Genet.* **104**, 65–75 (2019).
- Winkler, T. W. et al. The influence of age and sex on genetic associations with adult body size and shape: a large-scale genome-wide interaction study. *PLoS Genet.* 11, e1005378 (2015).
- 31. Consortium, G. T. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* **369**, 1318–1330 (2020).
- 32. Flannick, J. et al. Sequence data and association statistics from 12,940 type 2 diabetes cases and controls. *Sci. Data* **4**, 170179 (2017).
- Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat. Genet.* 50, 1505–1513 (2018).
- Scott, R. A. et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. *Nat. Genet.* 44, 991–1005 (2012).
- Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* 590, 290–299 (2021).
- Regier, A. A. et al. Functional equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human genetics projects. *Nat. Commun.* 9, 4038 (2018).
- Khan, A. T. et al. Recommendations on the use and reporting of race, ethnicity, and ancestry in genetic research: experiences from the NHLBI Trans-Omics for Precision Medicine (TOPMed) program. Preprint at https:// arxiv.org/abs/2108.07858 (2021).
- Haeckel, R. et al. Comparability of blood glucose concentrations measured in different sample systems for detecting glucose intolerance. *Clin. Chem.* 48, 936–939 (2002).
- Gogarten, S. M. et al. Genetic association testing using the GENESIS R/ Bioconductor package. *Bioinformatics* 35, 5346–5348 (2019).
- Brody, J. A. et al. Analysis commons, a team approach to discovery in a bigdata environment for genetic epidemiology. *Nat. Genet.* 49, 1560–1563 (2017).
- Conomos, M. P., Miller, M. B. & Thornton, T. A. Robust inference of population structure for ancestry prediction and correction of stratification in the presence of relatedness. *Genet. Epidemiol.* **39**, 276–293 (2015).
- 42. Lake, S. L. et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. *Hum. Hered.* **55**, 56–65 (2003).
- The NHGRI Genome Sequencing Program (GSP). Functional Annotation of Variants - Online Resource (FAVOR) Server. http://favor.genohub.org (2020).
- 44. Laakso, M. et al. The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases. *J. Lipid Res.* **58**, 481–493 (2017).
- Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nat. Genet.* 50, 1335–1341 (2018).
- Gaulton, K. J. et al. A map of open chromatin in human pancreatic islets. *Nat. Genet.* 42, 255–259 (2010).
- Varshney, A. et al. Genetic regulatory signatures underlying islet gene expression and type 2 diabetes. Proc. Natl Acad. Sci. USA 114, 2301–2306 (2017).

Acknowledgements

The Analysis Commons was funded by R01HL131136. Diabetes Genome Atlas (DGA) Processed data files were downloaded from the DGA website. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from the GTEx Portal on 04/05/20. Alisa K. Manning was supported by NIH K01 DK107836. Bertha Hidalgo was supported by K01 HL130609 01. Brian E. Cade is supported by K01-HL135405, American Thoracic Society Foundation Unrestricted Grant (Sleep). Ching-Ti Liu was supported by U01DK078616. Chloé Sarnowski was supported by U01DK078616. Daniel DiCorpo was supported by U01DK078616. Daniel E. Weeks was supported by R01 HL093093, R01 HL133040. Heather M was funded by NHLBI training grant T32 HL007055, T32 HL129982-03, ADA Grant #1-19-PDF-045, R01HL142825, R56HG010297, R01HG010297, U01HG007416, U01HG004803, R56HG010297, R01HG010297, U01HG007416, and U01HG004803. Heming Wang Sleep Research Society Foundation Career Development Award 018-JP-18, R35-HL135818, R01-HL113338. James B Meigs was supported by U01DK078616, NIDDK T2D AMP Opportunity Pool OP6. Jiang He was supported by U01HL072507, R01HL087263, and R01HL090682. Jose Florez was supported by NIH/NIDDK U01 DK105554 (J. Florez, PI), NIH/NIDDK U01 DK078616 (J. Meigs, PI) and NIH/NIDDK K24 DK110550 (J. Florez, PI). Josée Dupuis was supported by U01DK078616. Sheila Gaynor was supported by NIH/NHLBI 1OT3HL147154-01. Natalie Hasbani was supported by American Heart Association grant number 18CDA34110116. Paul de Vries was supported by American Heart Association grant number 18CDA34110116. Peitao Wu is supported by U01DK078616. Robert Sladek was supported by NIH/NIDDK U01 DK078616 (J. Meigs, PI). Ryan L. Minster was supported by R01 HL093093, R01 HL133040. Samantha Lent was supported by NIH/NIDDK (U01DK078616) and NIGMS (grant T32GM074905). Simin Liu was supported by AHA/18UNPG33750001; R01DK125403; R01ES029082. Xihong Lin was supported by NIH/NCI R35 CA197449, NIH/ NHGRI U01HG009088. Stephen T McGarvey was supported by R01 HL093093, R01 HL133040. Laura M. Raffield was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2TR002490 (LMR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. LMR was also funded by T32 HL129982. Susan Redline was supported by R35-HL135818, R01-HL113338. Lu Chen Weng is supported by the American Heart Association (18SFRN34110082). Jennifer Wessel is supported by American Heart Association 15SDG22210003, and Indiana University Grand Challenge Precision Health Initiative-Diabetes. Huichun Xu was supported by the AHA grant (19CDA34760258). Amish Study: We gratefully thank our Amish community and research volunteers for their longstanding partnership in research, and acknowledge the dedication of our Amish liaisons, field workers, and the Amish Research Clinic staff, without which these studies would not have been possible. The Amish studies are supported by grants and contracts from the NIH, including R01 AG18728, R01 HL088119, U01 GM074518, U01 HL072515, U01 HL84756, U01 HL137181, R01 DK54261, the University of Maryland General Clinical Research Center, grant M01 RR 16500, and the Mid-Atlantic Nutrition Obesity Research Center grant P30 DK72488, the Baltimore Diabetes Research and Training Center grant P60DK79637. Atherosclerosis Risk in Communities Study: The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, and HHSN268201700005I). The authors thank the staff and participants of the ARIC study for their important contributions. CES Study: The Cleveland Family Study has been supported by National Institutes of Health grants (R01-HL046380, KL2-RR024990, R35-HL135818, and R01-HL113338). CHS Study: This research was supported by contracts 75N92021D00006, HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grants R01HL120393, U01HL080295 and U01HL130114 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Framingham Heart Study: WGS for "NHLBI TOPMed: Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study (phs000974.v1.p1) was performed at the Broad Institute of MIT and Harvard (3R01HL092577-06S1 (AFGen)). This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine. The Framingham Heart Study (FHS) acknowledges the support of contracts NO1-HC-25195, HHSN268201500001I, and 75N92019D00031 from the National Heart, Lung and Blood Institute and grant supplement R01 HL092577-06S1 for this research. We also acknowledge the dedication of the FHS study participants without whom this research would not be possible. GeneSTAR Study: GeneSTAR was supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (U01 HL72518, HL087698, HL49762, HL59684, HL58625, HL071025, HL092165, HL099747, K23HL105897, HL112064), by grants from the National Institutes of Health/National Institute of Nursing Research (NR0224103, NR008153), by a grant from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NS062059), by a grant from the National Institutes of Health/National Center for Research Resources (M01-RR000052) to the Johns Hopkins General Clinical Research Center, and by a grant from the National Center for Advancing Translational Sciences, National Institutes of Health (UL1TR001079) to the Johns Hopkins Institute for Clinical & Translational Research. GENOA Study: Support for GENOA

ARTICLE

was provided by the National Heart, Lung and Blood Institute (HL054457, HL054464, HL054481, HL119443, HL085571, and HL087660) of the National Institutes of Health. We would like to thank the Mayo Clinic Genotyping Core, the DNA Sequencing and Gene Analysis Center at the University of Washington, and the Broad Institute for their genotyping and sequencing services. We would also like to thank the GENOA participants. Gen Salt Study: Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM109036 and by research grants U01HL072507, R01HL087263, and R01HL090682 from the National Heart Lung and Blood Institute of the National Institutes of Health, Bethesda, Maryland, USA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. GOLDN Study: GOLDN biospecimens, baseline phenotype data, and intervention phenotype data were collected with funding from National Heart, Lung and Blood Institute (NHLBI) grant U01 HL072524. Whole-genome sequencing in GOLDN was funded by NHLBI grant R01 HL104135-04S1. We thank GOLDN participants and investigators for their significant contributions. HyperGEN Study: The HyperGEN Study is part of the National Heart, Lung, and Blood Institute (NHLBI) Family Blood Pressure Program; collection of the data represented here was supported by grants U01 HL054472 (MN Lab), U01 HL054473 (DCC), U01 HL054495 (AL FC), and U01 HL054509 (NC FC). The HyperGEN: Genetics of Left Ventricular Hypertrophy Study was supported by NHLBI grant R01 HL055673 with wholegenome sequencing made possible by supplement-18S1. Jackson Heart Study: The Jackson Heart Study is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I) and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I, and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Minority Health and Health Disparities (NIMHD). The authors thank the participants and data collection staff of the Jackson Heart Study. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services. MESA & MESA Family Study: Whole-genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). WGS for "NHLBI TOPMed: Multi-Ethnic Study of Atherosclerosis (MESA)" (phs001416.v1.p1) was performed at the Broad Institute of MIT and Harvard (3U54HG003067-13S1). Centralized read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1, contract HHSN268201800002I). Phenotype harmonization, data management, sample-identity QC, and general study coordination, were provided by the TOPMed Data Coordinating Center (3R01HL-120393; U01HL-120393; contract HHSN268180001I). MESA and the MESA SHARe projects are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420. MESA Family is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support is provided by grants and contracts R01HL071051, R01HL071205, R01HL071250, R01HL071251, R01HL071258, R01HL071259, by the National Center for Research Resources, Grant UL1RR033176. Also supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center, San Antonio Family Study: Collection of the San Antonio Family Study (SAFS) data was supported in part by the following grants from the National Institutes of Health: P01 HL045522; R01 MH078111; R01 MH078143; R01 MH083824; R01 DK042273; R01 DK047482; and R01 DK053889. Whole-genome sequencing of the SAFS subjects was supported by U01 DK085524 and R01 HL113323. We are very grateful to the participants of the San Antonio Family Study for their continued involvement in our research programs, Samoan Study: Samoan Study - Data collection was funded by NIH grant R01-HL093093 and data analysis was funded by NIH grant R01-HL133040. We thank the Samoan participants of the study

and local village authorities. We acknowledge the support of the Samoan Ministry of Health and the Samoa Bureau of Statistics for their support of this research. *WHI Study:* The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN 268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C.

Author contributions

D.D. and S.M.G. contributed equally to this work. D.D., S.M.G., E.M.R., K.E.W., L.M.R., X.L, J.D., J.B.M., J.W., and A.K.M. contributed to writing. D.D., S.M.G., T.D.M., and A.K.M. analyzed data. D.D., E.M.R., and A.J. provided replication results. D.D., T.D.M., P.W., C.S., H.M.H., J.W., and A.K.M. contributed to trait harmonization efforts. S.M.G., X.L., J.D., J.B.M., J.W., and A.K.M. contributed to trait harmonization efforts. S.M.G., X.L., J.D., J.B.M., J.W., and A.K.M. provided annotation information. H.M.H., J.I.R., X.L., J.D., J.B.M., J.W., and A.K.M. provided leadership. D.D, S.M.G, E.M.R, K.E.W, L.M.R., T.D.M., P.W., C.S., H.M.H., AJ, N.R.H., P.S.V., J.A.B., B.H., X.G., J.A.P., J.R.O., S.Len., M.E.M., B.E.C., D.J., H.W., R.D.A., A.V., L.R., L.L., N.D.P., M.A., J.M.P., S.A., AS.B., A.G.B., L.F.B., C.S.C., Y.D.I.C., W.J.C., M.O.G., J.S.F., M.R.I., R.R.K., T.N.K, S.Lee, C.T.L., D.L., J.E.M., RL.M., T.N., J.S.P., LJ.R.T, A.P.R., M.S.R., E.S., J.A.S., D.E.W., H.X., J.Y., W.Z., S.P., A.A., D.K.A., J.B., E.B., A.C., L.A.C., J.E.C., R.D., J.H., S.R.H., SL.R.K., R.W.K., C.K., S.Li, R.A.M., S.T.M., B.D.M., A.C.M., P.A.P., B.M.P., S.R., A.R.S., K.D.T., R.S.V., K.A.V.M., J.C.F., J.G.W, R.S., S.S.R., J.I.R., X.L., J.D., J.B.M., J.W, and A.K.M. contributed to manuscript review.

Competing interests

Jose Florez has received a consulting honorarium from Goldfinch Bio. and speaker fees from Novo Nordisk. James S. Floyd has consulted for Shionogi Inc. Bruce M. Psaty serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. Stella Aslibekyan holds equity in 23andMe, Inc.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s42003-022-03702-4.

Correspondence and requests for materials should be addressed to Jennifer Wessel or Alisa K. Manning.

Peer review information *Communications Biology* thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling Editors: Chiea Chuen Khor and Luke R. Grinham.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/.

© The Author(s) 2022

Daniel DiCorpo^{1,70}, Sheila M. Gaynor^{2,70}, Emily M. Russell³, Kenneth E. Westerman ^{4,5,6}, Laura M. Raffield ⁷, Timothy D. Majarian⁵, Peitao Wu¹, Chloé Sarnowski ¹, Heather M. Highland ⁸, Anne Jackson⁹, Natalie R. Hasbani¹⁰, Paul S. de Vries¹¹, Jennifer A. Brody^{12,13}, Bertha Hidalgo¹⁴, Xiuqing Guo¹⁵, James A. Perry ^{16,17}, Jeffrey R. O'Connell^{16,17}, Samantha Lent ¹, May E. Montasser ¹⁶, Brian E. Cade^{18,19,20}, Deepti Jain²¹, Heming Wang^{18,19,20}, Ricardo D'Oliveira Albanus²², Arushi Varshney²², Lisa R. Yanek ²³,

Leslie Lange²⁴, Nicholette D. Palmer ²⁵, Marcio Almeida²⁶, Juan M. Peralta²⁶, Stella Aslibekyan²⁷, Abigail S. Baldridge²⁸, Alain G. Bertoni²⁹, Lawrence F. Bielak³⁰, Chung-Shiuan Chen³¹, Yii-Der Ida Chen¹⁵, Won Jung Choi³², Mark O. Goodarzi³³, James S. Floyd^{34,35}, Marguerite R. Irvin¹⁴, Rita R. Kalyani²³, Tanika N. Kelly³¹, Seonwook Lee³², Ching-Ti Liu ¹, Douglas Loesch^{17,36,37}, JoAnn E. Manson^{6,38}, Ryan L. Minster ³, Take Naseri³⁹, James S. Pankow⁴⁰, Laura J. Rasmussen-Torvik²⁸, Alexander P. Reiner⁴¹, Muagututi'a Sefuiva Reupena⁴², Elizabeth Selvin⁴³, Jennifer A. Smith ^{30,44}, Daniel E. Weeks^{3,45}, Huichun Xu^{16,17}, Jie Yao¹⁵, Wei Zhao³⁰, Stephen Parker^{22,46}, Alvaro Alonso ⁴⁷, Donna K. Arnett ⁴⁸, John Blangero ²⁶, Eric Boerwinkle¹⁰, Adolfo Correa⁴⁹, L. Adrienne Cupples ^{1,50}, Joanne E. Curran ²⁶, Ravindranath Duggirala²⁶, Jiang He³¹, Susan R. Heckbert ^{34,41}, Sharon L. R. Kardia³⁰, Ryan W. Kim³², Charles Kooperberg ⁵¹, Simin Liu ⁵², Rasika A. Mathias ²³, Stephen T. McGarvey⁵³, Braxton D. Mitchell^{16,17,54}, Alanna C. Morrison ¹⁰, Patricia A. Peyser³⁰, Bruce M. Psaty ^{12,13,41,55}, Susan Redline ^{18,19,56}, Alan R. Shuldiner⁵⁷, Kent D. Taylor ¹⁵, Ramachandran S. Vasan ^{50,58,59}, Karine A. Viaud-Martinez⁶⁰, Jose C. Florez^{5,6,20,61}, James G. Wilson⁶², Robert Sladek ^{63,64}, Stephen S. Rich ⁶⁵, Jerome I. Rotter ¹⁵, Xihong Lin², Josée Dupuis ¹, James B. Meigs^{6,20,66}, Jennifer Wessel ^{67,68,69 &} & Alisa K. Manning ^{4,5,6 &}

¹Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA, ²Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. ³Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA. ⁴Clinical and Translational Epidemiology Unit, Mongan Institute, Massachusetts General Hospital, Boston, MA 02114, USA. ⁵Metabolism Program, The Broad Institute of MIT and Harvard, Cambridge, MA 02124, USA. ⁶Department of Medicine, Harvard Medical School, Boston, MA 02115, USA, ⁷Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA, ⁸Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA. ⁹Department of Biostatistics, University of Michigan, Ann Arbor, MI 48109, USA. ¹⁰Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. ¹¹Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. ¹²Cardiovascular Health Research Unit, University of Washington, Seattle, WA 98101, USA. ¹³Department of Medicine, University of Washington, Seattle, WA 98101, USA. ¹⁴Ryals School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294, USA. ¹⁵The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA. ¹⁶Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA. ¹⁷Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. ¹⁸Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA 02115, USA. ¹⁹Division of Sleep Medicine, Harvard Medical School, Boston, MA 02115, USA. ²⁰Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA 02124, USA. ²¹Department of Biostatistics, University of Washington, Seattle, WA 98195, USA. ²²Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA. ²³GeneSTAR Research Program, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. ²⁴Department of Medicine, Anschutz Medical Campus, University of Colorado Denver, Aurora, CO 80045, USA. ²⁵Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. ²⁶Department of Human Genetics and South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley School of Medicine, Brownsville and Edinburg, TX 78539, USA. ²⁷23andMe, Sunnyvale, CA 94086, USA. ²⁸Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. ²⁹Department of Epidemiology & Prevention, Wake Forest School of Medicine, Winston-, Salem, NC 27157, USA. ³⁰Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA. ³¹Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine. New Orleans. LA 70112, USA. ³²Psomagen, Inc, Rockville, MD 20850, USA. ³³Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. ³⁴Cardiovascular Health Research Unit, University of Washington, Seattle, WA 98195, USA. ³⁵Department of Medicine, University of Washington, Seattle, WA 98195, USA. ³⁶Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA. ³⁷Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. ³⁸Brigham and Women's Hospital, Boston, MA 02115, USA. ³⁹Ministry of Health, Government of Samoa, Apia, Samoa. ⁴⁰Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454, USA. ⁴¹Department of Epidemiology, University of Washington, Seattle, WA 98195, USA. ⁴²Lutia i Puava 'ae Mapu i Fagalele, Apia, Samoa. ⁴³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21287, USA. ⁴⁴Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA. ⁴⁵Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA. ⁴⁶Department of Human Genetics, University of Michigan, Ann Arbor, MI 48109, USA. ⁴⁷Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA. ⁴⁸College of Public Health, University of Kentucky, Lexington, KY 40506, USA. ⁴⁹Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39211, USA. ⁵⁰National Heart Lung and Blood Institute and Boston University's Framingham Heart Study, Framingham, MA 01702, USA. ⁵¹Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. ⁵²Center for Global Cardiometabolic Health (CGCH), Boston, MA 02215, USA. ⁵³International Health Institute and Department of Epidemiology, Brown University School of Public Health, Providence, RI 02912, USA. ⁵⁴Geriatrics Research and Education Clinical Center, Baltimore VA Medical Center, Baltimore, MD 21201, USA. ⁵⁵Department of Health Services, University of Washington, Seattle, WA 98101, USA. ⁵⁶Division of Pulmonary, Critical Care, and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA. ⁵⁷Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, MD 21231, USA. ⁵⁸Evans Department of Medicine, Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, MA 02118, USA. ⁵⁹Evans Department of Medicine, Whitaker Cardiovascular Institute and Cardiology Section, Boston University School of

Medicine, Boston, MA 02118, USA.⁶⁰Illumina Laboratory Services, Illumina, Inc, San Diego, CA 92122, USA.⁶¹Center for Genomic Medicine and Diabetes Unit, Massachusetts General Hospital, Boston, MA 02114, USA.⁶²Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.⁶³Department of Human Genetics, McGill University, Montreal, Montreal, Quebec H3A 0G1, Canada. ⁶⁴Department of Medicine, McGill University, Montreal, Montreal, Quebec H3A 0G1, Canada..⁶⁵Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22908, USA.⁶⁶Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. ⁶⁷Department of Epidemiology, Fairbanks School of Public Health, Indiana University, IN 46202, USA.⁶⁸Department of Medicine, School of Medicine, Indiana University, IN 46202, USA.⁶⁹Diabetes Translational Research Center, Indiana University, IN 46202, USA.⁷⁰These authors contributed equally: Daniel DiCorpo, Sheila M. Gaynor.⁵⁸email: wesselj@iu.edu; amanning@broadinstitute.org